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I 
Introduction 
___________________________________ 
    
 
1.1 Metabolism of fatty acids 
 
1.1.1   Role of fatty acids 
Fatty acids (FAs) are a major source of energy for many tissues or organs in 
animals, especially for muscle, kidney and liver. Produced by lipolysis mostly from 
adipose tissue, FAs are transported bound to plasma albumin in the blood and are 
taken up by tissues via transport proteins present in the plasma membrane. In 
lipogenic tissues like the liver, white adipose tissue (WAT) and kidney, FAs can be 
synthesised de novo from glucose following glycolysis. These tissues are therefore 
major targets for the regulation of gene expression which is crucial for metabolism.  
Inside cells, FAs have various targets depending on the tissue and its metabolic 
functions. For instance, they can be elongated, desaturated, oxidised for energy 
production, peroxidised, exchanged with phospholipids and are substrates for 
eicosanoid biosynthesis. Long-chain fatty acids (LCFAs) are critically important in 
cellular homeostasis as they are involved in a wide variety of processes including 
post-translational modifications of proteins, cell signalling, membrane permeability, 
and regulation of transcription.  
 
1.1.2    Mitochondrial  β-oxidation 
The theory of ß-oxidation started in 1904, when Knoop could demonstrated that the 
oxidation of FAs begins at carbon atom 3, the β-carbon, causing it to yield FAs 
shortened by two carbon atoms (Vance  and Vance, 2002).  
The ß-oxidation of FAs is a complex pathway involving in the case of saturated 
LCFAs at least 16 proteins which are associated with the inner mitochondrial 
membrane and matrix. It is a central metabolic process supplying electrons to the 
respiratory chain and thus energy for the aerobic organisms, and it is of particular 
importance for cardiac and skeletal muscles. Moreover, a number of other tissues, 
primarily the liver but also the kidney, smal intestine and WAT, can utilise the                                                                                                                            I. Introduction  
     2
products of ß-oxidation for the formation of ketone bodies (acetoacetate and ß-
hydoxybutyrate) which are important fuels for extrahepatic organs (e.g. brain).   
 
1.1.3  The mitochondrial carnitine palmityltransferase system 
After entry into the cell and before their catabolism, LCFAs are activated to acyl-
CoA esters by acyl-CoA synthetases localised in the mitochondrial outer 
membrane. Acyl-CoA esters cannot directly cross the mitochondrial inner 
membrane but require carnitine and three proteins including carnitine 
palmitoyltransferase-I (CPT-I), the carnitine acylcarnitine carrier (CAC), and 
carnitine palmitoyltransferase-II (CPT-II) for this process (Fig. 1). 
 
 
 
Figure 1.1    Mitochondrial carnitine palmitoyltransferase systhem . (Taken from Prasad 
et al., 2001). 
 
The first enzyme, CPT-I is localised in the outer-mitochondrial membrane and 
converts the fatty acyl-CoA ester to it's carnitine ester. The carnitine ester is 
subsequently transported across the mitochondrial inner membrane by CAC. Once 
inside the mitochondrial lumen, CPT-II, which is bound to the mitochondrial inner 
membrane facing the mitochondrial matrix, reconverts the carnitine ester to the CoA 
ester, which can then serve as a substrate for ß-oxidation.                                                                                                                             I. Introduction  
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1.1.4   Carnitine palmitoyltransferase-I 
Carnitine palmitoyltransferase-I (CPT-I) is an enzyme that catalyses the regulatory 
step of LCFA translocation into the mitochondrial matrix. The other components of 
the fatty acid-translocating system are generally not considered to play a significant 
regulatory role in the transport of LCFAs into the mitochondrial matrix.  
It is generally accepted  that the oxidation of LCFA  is regulated at the level of CPT-
I through different mechanisms: (1) changes in CPT-I activity, (2) changes in the 
concentration of malonyl-CoA. Malonyl-CoA is the product of the reaction catalysed 
by key enzyme of FA synthesis, acetyl-CoA carboxylase (ACC) and is a 
physiological inhibitor of CPT-I, (3) changes in CPT-I sensitivity to malonyl-CoA 
inhibition (Girard et  al., 1992). The last two, so caled malonyl-CoA- dependent 
mechanisms of regulation are generally regarded as short-term controls of CPT-I 
activity and differ from long-term regulation in response to alterations in the 
nutritional and hormonal status of the animal. During the last years, however, a 
novel mechanism of short-term control of CPT-I has been proposed. This is the 
malony-CoA-independent stimulation of CPT-I, which involves modulation of 
interactions between CPT-I and cytoskeletal components. This modulation may rely 
on the Ca
+2/calmodulin-dependent protein kinase II (CM-PKII) cascade and 5'-AMP-
activated protein kinase (AMPK) activation. Several observations suggested that 
the control of CPT-I is a concerted action of malonyl-CoA-dependent and  
-independent mechanisms (Valesco et al., 1997; Valesco et al., 1998).       
The results of previous studies suggested that the regulation of CPT-I gene 
expression is dependent on hormonal (e.g. glucagon, insulin, thyroid hormones) 
and nutritional factors (e.g. FA, carnitine). It is known that rat liver CPT-I gene 
expression (and enzyme activity) increases dramaticaly after birth, and also during 
the translation from the fed to starved  state in the adult animals (Girard et al., 1992; 
Thumelin  et al., 1994). In both these situations there is an increase of plasma 
glucagon, cAMP, thyroid hormones and decrease of plasma insulin. Under these 
conditions, there is also a marked increases in CPT-I activation and CPT-I mRNA 
and protein level. Another potential regulator of CPT-I and FA oxidation may be 
hydrogen ion accumulation. It was found that small changes in pH-level from 7.0 to 
6.8 inhibited CPT-I activity by 50% (Starritt et al., 2000). Such changes in pH-level 
can be observed during intensive exercise and hypoxia (Jeukendrup, 2002). 
                                                                                                                            I. Introduction  
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1.1.5   Hepatic carnitine palmitoyltransferase I isoform 
Two kineticaly different isoforms, namely hepatic CPT-Iα and muscle CPT-Iβ, have 
been described with distinct tissue distributions and are encoded by different genes 
localised on chromosome 11q13 and 22q13, respectively (Britton at al., 1997).   
The full length cDNA encoding rat and human liver CPT-Iα has been isolated and 
characterised (Esser et al., 1993; Britton et al., 1995). The rat cDNA contains an 
open reading frame of 2319 bases, predicting a 773-amino acid protein of 88 kDa. It 
was shown that CPT-Iα protein adopts a bitopic location within the mitochondrial 
outer membrane; it has two transmembrane domains, and both the N- and C- 
termini are exposed on the cytosolic side of the membrane, whereas the linker 
region between the transmembrane domains protrudes into the intermembrane 
space (Fraser et al., 1997) (Fig. 1.2.). 
 
 
 
Figure 1. 2  Topology of CPT-Iα within the mitochondrial outer membrain.  
TMD, transmembrane domains; Cyto, cytosolic side; Ims, intramembrane space;  
OM, mitochondrial outer membrane. (Taken from Fraser et al., 1997). 
 
CPT-Iα is found in most cells including heart, liver and renal mesangial cells,   
however, is not present in skeletal muscle cells and white adipocytes. CPT-Iß is 
expressed in skeletal muscle, brown and white adipocytes and heart (Cook et al., 
2001). The regulation of these isoforms is considerably different in terms of enzyme 
activity and gene expression. For instance, the sensitivity of CPT-Iα to malonyl-CoA 
inhibition is increased by insulin and decreased by thyroid hormone, while the 
sensitivity of CPT-Iß is not altered by these hormones. Interestingly, it was shown 
that development as well as hormonal and nutritional control of CPT-Iα have                                                                                                                            I. Introduction  
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different effects in liver and heart (Cook et al., 2001). This result suggested that 
CPT-Iα is regulated also in a tissue- specific manner. However, little is known about 
differences in CPT-Iα regulation in liver and renal mesangial cells (or another renal 
cells),  especially under inflammatory conditions. The present study was focused on 
only the characterisation of the CPT-Iα isoform in rat mesangial cells and primary 
hepatocytes.   
 
1.1.6   Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 
(mHMG-CoA synthase) 
HMG-CoA synthase catalyses the condensation of acetoacetyl-CoA and acetyl-CoA 
to form HMG-CoA plus free CoA. Two HMG-CoA synthase isoforms were localised 
in the cytosolic and mitochondrial compartments and characterised as products of 
two different genes (Ayte et al.,1990; Gil-Go`lmez et al., 1993). The mitochondrial 
HMG-CoA synthase is an important control site of ketogenensis, a mitochondrial 
process  by which acetyl-CoA, mostly derived from the ß-oxidation of fatty acids, is 
converted through four reactions into acetoacetate, ß-hydroxybutyrate and acetone, 
all of which are ketone bodies (Fig.1.3). 
 
 
Figure  1. 3    Schematic representation of the HMG-CoA pathway. (Taken from Hegardt , et 
al.,  1999). 
 
The utilisation of fatty acids for ketogenensis is also largely controlled by CPT-Iα in 
hepatocytes (McGarry and Brawn, 1997) and other tissues (Bla`zquez et al., 1998) 
and the promoters of both enzymes contain similar DNA regulatory elements 
necessary to modulate the expression by cAMP, insulin and fatty acid (Hegardt, 
1998; Hegardt, 1999; Chatelain et al., 1996).    
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1.2     Nitric oxide (NO)  
 
Nitric oxide (NO) is a multifunctional mammalian effector that is involved in 
numerous biological processes, such as neurotransmission, vasodilation, immune 
modulation, and regulation of apoptosis (Krönke et al., 1995; Huwiler and 
Pfeilschifter, 2003; Beck et al., 1999).  
It is synthesised from L-arginine by the enzyme nitric-oxide synthase (NOS), which 
requires the cofactor tetrahydrobiopterin (BH4) for maximal activity. NOS catalyses 
the oxidation of the terminal guanidino group atom of L-arginine to form L-citrulline 
and NO. Details of this mechanism are controversial, but it is known that NOS 
enzymes combine oxygenase and reductase activities associated with distinct 
structural domains. The oxygenase domain contains heme, while the reductase 
domain binds calcium-calmodulin, flavin mononucleotide (FMN), flavin adenine 
dinucleotide (FAD) and NADPH. It is believed that the flavins accept electrons from 
NADPH and transfer them to the heme iron which  binds O2 and catalyses the 
stepwise oxidation of L-arginine to NO and citrulline.  
Three isoforms of NOSs have been identified and categorised into constitutive and 
inducible isotypes. Two distinct constitutively expressed NOSs, endothelial NOS 
(eNOS) and neuronal (nNOS), produce nanomolar amounts of NO. A third isoform, 
inducible (iNOS), is expressed in response to inflammatory cytokines in many cell 
types including hepatocytes and mesangial cells, and produces micromolar 
concentrations of NO.  
The result of many of the actions ( e.g. vasodilation) of NO leads to the formation of 
cGMP (Lucas et al., 2000). NO, formed by the cells, binds to a  heme moiety on the 
soluble guanylyl cyclase  and activates this enzyme to produce cGMP from GTP. 
The resulting increase of intracellular cGMP alters the activity of three main target 
proteins: (1) cGMP-regulated ion channels (2) cGMP-regulated 
phosphodiesterases, and (3) cGMP-dependent protein kinases (cGKs) (Schmidt et 
al., 1993). Moreover, in smooth muscle cells, the activation of cGKs leads to the 
inhibition of calcium influx and subsequently to a decrease in smooth muscle 
tension, causing vasodilation. 
Furthermore, NO affects gene expression by modulating transcription factors (e.g. 
NF-κB, AP-1), activating the MAPK cascade and in high concentrations directly 
causing damage of DNA (Beck KF et al., 1999). NO and its reaction products can                                                                                                                            I. Introduction  
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also modify protein functions through S-nitrosylation of thiol groups or nitration of 
tyrosine residues of proteins (Stamler, 1994). 
 
1.2.1   NO and inflammation  
Many  acute inflammatory diseases are associated with a massive production of 
NO. In particular, inflammatory kidney diseases and hepatic injuries are 
accompanied  by changes in the expression patterns of cytokines, growth factors 
and many more inflammatory mediators (Huwiler and Pfeilschifter, 1999 [a; b]). 
iNOS is rapidly upregulated in response to the endotoxin lipopolysaccharide (LPS), 
or proinflammatory cytokines (such as tumor necrosis factor-α (TNF-α), interleukin-
1ß (IL-1ß) or interferon-γ or combinations of these) within hours in hepatocytes and 
mesangial cells. These stimuli often act synergistically to induce iNOS expression, 
however, IL-1ß alone is an effective stimulator of iNOS in rat mesangial cells and 
hepatocytes (Pfeilschifter and Schwarzenbach, 1990). In rat mesangial cells and 
hepatocytes, the cytokine- mediated upregulation of iNOS gene transcription 
requires the presence of transcriptional factor NF-κB. NF-κB can bind to κB-
regulatory elements to enhance or to induce gene transcription and is a central 
regulator of a number of genes involved in cell adhesion, inflammatory responses, 
apoptosis, differentiation and proliferation (Eberhardt et al., 1998; Diaz-Guerra et 
al., 1996). 
  
1.2.2   NO in the regulation of fatty acid metabolism 
The regulation of CPT-I by NO was first described in 1996. After  feeding of the rats 
with a specific inhibitor of NO synthase N
G-monomethyl-L-arginine L-NMMA, a 
significant decrease in ketogenesis was observed. Furthermore, in these rats, 
hyperlipidemia and hypercholesteremia was dramaticaly induced. These changes 
were explained by a decrease in CPT-I activity and subsequently, in a massive 
disorder of lipid metabolism (Khedara et al., 1996). More recently, it was shown that 
the NO/cGMP signalling pathway  is involved in the stimulation of CPT-Iα activity in 
rat liver cells. The NO donors and cGMP analogs inhibited ACC, and thus, 
decreased the level of malonyl-CoA. Because malonyl-CoA is a potent inhibitor of 
CPT-I, its depletion led to a significant activation of CPT-Iα and increase in the rate 
of FA oxidation (Garcia- Villafranca et al., 2002).  
                                                                                                                            I. Introduction  
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1. 3    Hypoxia 
 
Hypoxia is a condition by which tissues and cells are insufficiently supplied with  
oxygen. Thereby, acute responses often result in changes in the activity of 
preexisting proteins, while chronic responses cause changes in gene expression. 
Gene products that augment O2 supply and enhance cell survival include 
erythropoietin which increases the proliferation  of erythrocytes, the angiogenic 
factor VEGF which stimulates growth of new capillaries, and induction of glycolytic 
enzymes which are important for ATP production.    
Hypoxia is the physiologic trigger that activates the hypoxia-inducible factor (HIF), a 
transcription factor which  is also up-regulated by certain transition metals (Co
2+, 
Ni
2+, Mn
2+) and by iron chelation (desferrioxamine (DFO)) (Wang and Semenza, 
1993; Goldberg et. al., 1988). It has been proposed that Co
+2 is incorporated into 
newly synthesised heme, thereby locking the O2 sensor into a deoxy configuration 
and therefore mimicking the effects of hypoxia.  
Under hypoxic conditions, HIF-1 binds to hypoxia-responsive element (HRE) on the 
promoter or enhancer of various hypoxia-inducible genes (Rees et al., 2001; 
Kakinuma  et al., 2001) including erythropoietin, vascular endothelial factor, glucose 
transport proteins, and glycolytic enzymes, as well as genes involved in iron 
metabolism. 
 HIF is a heterodimer that is composed of a HIF-Iα and HIF-Iß subunit. Hypoxia 
leads to the accumulation of HIF-Iα, dimerisation with HIF-Iß and to binding of this 
dimer to HIF-responsive elements (HRE) (Huang and Bunn, 2003). For some genes 
(e.g. glucose transporter-1), hypoxia-inducible expression is critically dependent on 
HIF-Iα, whereas for other genes (e.g. heme oxigenase-1, CPT-Iß) hypoxia-
inducible changes in their expression appeared to be largely independent of  
HIF-Iα expression (Janice et al., 2001).  
In mesangial cells and hepatocytes, hypoxia can develop due to different 
physiological circumstances. For instance, during normal development, glomeruli 
might be relatively ischemic/ hypoxic because of incompletely developed capillaries 
(Yuan et al., 2000). Chronic hypoxia is known to affect mesangial cell proliferation, 
matrix production and secretion of signaling molecules (Sahai et al., 1997; Kim et 
al., 1996). In liver, an oxygen gradient exists due to the unidirectional blood flow 
and to the oxygen-consuming metabolic processes of the cells. This gradient was                                                                                                                            I. Introduction  
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proposed to be an important regulator of the expression of genes encoding the key 
enzymes of the carbohydrate metabolism (Jungrmann and  Kitetzmann, 1996). 
 
1.3.1   Hypoxia and inflammation 
Hypoxia plays an important role in many pathophysiological  conditions  including  
ischemia, cancer, stroke. For instance, it has been shown that HIF-Iα and VEGF 
are upregulated in the myocardium during heart failure or acute coronary occlusion 
(Kakinuma  et al., 2001; Huang and Bunn, 2003). In renal inflammatory diseases 
where the capillary is obliterated or distracted, glomeruli can be regarded as   
ischemic /hypoxic  (Nangaku et al., 1997). Just as HIF has a critical role to play in 
growth and progression, it is beneficial in vascular remodelling, where HIF-
dependent genes are activated.  
Recent studies have shown that HIF-Iα is not only accumulated by hypoxia, but is 
also activated in normoxic cells in response to a variety of mediators, including IL-
1ß, growth factor (VEGF) and TNFα  (Stiehl et al., 2001). However, the induction of 
HIF-Iα by hypoxia is much more pronounced than by growth factors and cytokines 
(Huang and Bunn 2003). On the other hand, hypoxia activates HIF-I-dependent 
transcription factors to induce pro-inflammatory genes like interleukin-8 (IL-8), IL-6, 
cyclooxygenase-2 or secretoric phospholipases A2 (Michiels et al., 2002).  
 
1.3.2   Metabolic adaptation to hypoxia 
Energy metabolic responses have evolved to permit preservation of cellular function 
in hypoxic environments. One critical adaptive response involves the suppression of 
cellular energy consumption and improved efficiency of oxygen utilization during 
ATP production. Under hypoxic conditions, decreased oxygen consumption is 
achieved in part by increasing cellular glycolytic capacity while down-regulating 
mitochondrial fatty acid ß-oxidation. Despite recent progress in characterising the 
regulation of cellular glucose utilization in response to hypoxia, little is known about 
the mechanisms involved in hypoxia-mediated suppression of mitochondrial flux. 
Although, cardiac myocytes have been the subject of many investigations 
concerning the regulation of CPT-I and fatty acid oxidation, there are many 
discrepancies and open questions. For instance, it has been shown that CPT-Iα 
activity is significantly stimulated in hypoxic myocytes and suggesting that FAs are 
the preferred substrate in hypoxic/ischemic heart (Wang et al., 1998). However, a 
more recent study demonstrated that under hypoxia, LCFA-mediated transcriptional                                                                                                                            I. Introduction  
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activation of CPT-1ß is blocked by the PPAR/RXRα  pathway and causes an 
accumulation of lipids in cardiac myocytes (Huss et al., 2001). Even less clear is the 
regulation of CPT-Iα in liver and kidney under hypoxia, with no detailed studies 
available so far.  
 
1.4    Phospholipases  
 
Phospholipases A2 (PLA2) are widely distributed enzymes whose primary action is 
the hydrolysis of glycerophospholipids at the sn-2 position to yield free fatty acids, 
including arachidonic acid (AA), and lysophospholipids. These enzymes are 
classified in high-molecular-weight (85 kDa) cytosolic PLA2s (cPLA2s or group IV 
PLA2s), low-molecular-weight (13-16 kDa) secretory PLA2s (sPLA2s), calcium-
independent iPLA2s (85 kDa) and PAF acetylhydrolases (PAF-AH) (Kudo and 
Murakami, 2002). Cytosolic PLA2s  show a marked preference for AA over other 
fatty acids and are activated by Ca 
2+ and by phosphorylation (with the exception of 
the calcium-independent isoform cPLA2-γ). cPLA2s are located in the cytosol but 
translocate to the perinuclar and Golgi membranes when the intracellular Ca 
2+ 
rises above about 0.5 µM. AA released from membrane phospholipids by the action 
of cPLA2s is then used for the biosynthesis of eicosanoids as important lipid second 
messengers. Another intracellular form of PLA2s is the family of Ca 
2+ -independent 
PLA2s (iPLA2s), which are responsible for removing highly saturated FAs from 
phospholipids in order to incorporate more unsaturated FAs. e.g. AA into cellular 
phospholipids (phospholipid acyl chain remodeling) (Winstead et al., 2000). How 
iPLA2s bind to membranes, and whether they cycle between the membrane and 
soluble fractions, remains to be determined. Another group of Ca 
2+ -independent 
PLA2 enzymes of 30-40 kDa, care the platelet activating factor-acetylhydrolases 
(PAF-AHs). These enzymes have the capability to hydrolyse and inactivate the lipid 
mediator PAF, a phosphatidylcholine species that has a potent pro-inflammatory 
activity (Stafforini et al., 1997). The PLA2-family also includes a growing number of 
secreted enzymes, so-called secreted PLA2s (sPLA2). Several sPLA2s have been 
characterised and classified into different groups (group IB, IIA, IIC, IID, IIE, IIF, III, 
V, X, and XII) (Murakami and Kudo, 2004). Previous studies have shown that  these 
enzymes possess distinct physiological functions and display distinct, but yet 
partially overlapping tissue distribution patterns. sPLA2s are disulfide-rich proteins 
that display little FA chain specificity and hydrolyse the ester bond of                                                                                                                            I. Introduction  
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glycerophospholipids in the presence of mM concentrations of Ca
2+ (Murakami and 
Kudo, 2004). 
Both cPLA2 and sPLA2 have been implicated in various physiological and 
pathological functions including lipid digestion, release of proinflammatory 
mediators, cell proliferation, ischemic injury, inflammatory disease, cancer, and anti-
bacterial defence.  
 
1.4.1  Properties of group IIA PLA2 (sPLA2 IIA) and its expression 
in inflammation 
sPLA2-IIA is constitutively expressed in various tissues related to the immune 
response (e.g. spleen, thymus), as well as in the intestine and liver cells. 
Inflammatory effector cells such as neutrophils and mast cells store sPLA2-IIA in 
their secretory granules and release it following cell activation. Renal mesangial 
and liver cells also secrete sPLA2-IIA, however, only in response to pro-
inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α 
(TNFα), lipopolysaccharide (LPS) and cAMP-elevating or -mimicing agents. 
Moreover, an increase in sPLA2  mRNA level in hypoxic endothelial cells was 
detected (Michels, et al, 2002). It has been clearly demonstrated that the secreted 
enzyme  participates in the propagation of chronic inflammatory processes and 
allergic diseases such as rheumatoid arthritis (Seilhamer et al., 1989; Bertsch et al., 
1999; Talvinen et al., 2001), sepsis and glomerulonephritis (Scholz-Pedretti et al., 
2002).  
The mechanism of sPLA2-IIA activation and its functions during inflammation are 
still under active investigation. sPLA2-IIA has low functional capability on the 
surface of intact cells because of its weak binding capacity to the external leaflet of 
the plasma membrane (interfacial binding). However, in activated cells with 
perturbed membranes, which occur during inflammation, sPLA2-IIA can be sorted 
into the caveolin-rich vesicular and perinuclear compartment membranes (Golgi, 
endoplasmic reticulum, and nuclear envelope) through binding to GPI-anchored 
glypican, a glycosylphosphatidylinositol (GPI)-anchored heparan sulfate 
proteoglycan (HSPG) (Murakami  et al, 2002). It is tempting to speculate that 
glypican binding and sorting of sPLA2-IIA into specific subcellular compartments 
can contribute to more efficient AA release and  to the cyclooxygenase (COX-2)-
dependent prostaglandin E2 (PGE2) biosynthesis. On the other hand,  more recent 
studies do not support this hypothesis, as it was demonstrated that AA release by                                                                                                                            I. Introduction  
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exogenously added sPLA2-IIA does not require HSPG glypican and that this 
enzyme is inefficient at liberating AA from mammalian cells. There is some 
evidence that the action of cPLA2 is a prerequisite for sPLA2 function in cells and 
that cPLA2 is responsible for most of the AA release in stimulated cells (Mounier et 
al., 2004). In addition, further studies have shown that exogenous addition of 
sPLA2-IIA to mammalian cells leads to activation of mitogen activated protein 
kinase (MAPK) and protein kinase C (PKC), which then phosphorylates and thus 
activates cPLA2α (Huwiler et al., 1997; Han et al., 2003).   
 
1.4.2   Phospholipases in regulation of FAs metabolism 
Although PLAs are commonly involved in the digestion of nutrients and the 
formation of bioactive molecules involving FAs and their metabolites, there are no 
studies about regulation of FA oxidation and CPT-I by sPLAs.  
FAs or their metabolites released  by sPLAs under inflammatory conditions may 
activate  CPT-Iα gene transcription and subsequently  FA oxidation via activation of 
nuclar receptors of the steroid-thyroid superfamily, the peroxisome-proliferator- 
activated receptor (PPAR) (Clarke et al., 2003). It is known that diverse FAs bind 
and activate all three PPAR isoforms, PPARα, PPARδ/β and PPARγ , with varying 
specificities (Corton et al., 2000; Lee et al., 2003). Ligand-activated PPARs 
recognise PPAR response elements (PPRE) upon heterodimerisation with the 
retinoic X receptor (RXR). FAs with chain lengths under 16 and over 22 carbons 
only weakly activate PPARs, if at all. PPARα is mainly expressed in liver and 
kidney, exhibiting strong binding affinity for both saturated and unsaturated FAs. 
Although the CPT Iα gene promoter possess a PPRE, where is located between 
2859 and 2846 base pairs upstream of the start codon, the contribution of PPAR in 
mediating effects of LCFAs on CPT-Iα regulation remains controversial and the 
molecular mechanisms by which FAs may regulate this gene transcription are still 
unclear. In rat liver, for example, LCFA induced CPT-Iα gene transcription through 
a PPARα-independent mechanism owing to a sequence located in the first intron of 
the gene (Louet et al., 2001[a,b]). By contrast, it has been shown that the LCFA-
dependent upregulation of mHMG-CoA synthase expression, whese gene promoter 
also includes PPRE in the 5' upstream region, is clearly mediated by PPARα. 
  Another possible mechanism of CPT-Iα activation by sPLAs may include the 
MAPK signalling pathway. MAPK are known to phosphorylate, and thereby activate                                                                                                                            I. Introduction  
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many transcripton factors (for instance, nuclear factors) which may play a 
regulatory role in CPT-Iα expression. Also, the reciprocal connection and cross-
regulation between cPLA2s and sPLA2 followed by an additive increase in  FAs 
level involves PKC and MAPK. Thus, a MAPK-mediated activation of PLA2s and 
subsequent increase in FFAs can significantly contribute to CPT-Iα regulation.  
 
1.5   Rat  mesangial  cells 
 
The glomerulus is part of the nephron, the smallest functional unit of the kidney, 
and is made by four cell types: endothelial cells outlining the glomerular capillaries, 
mesangial cells functioning as pericytes, visceral glomerular epithelial cells, named 
podocytes, and parietal glomerular epithelial cells (Remuzzi and Bertami, 1998). 
Glomerular mesangial cells are crucial for processes maintaining the glomerular 
filtration rate. On the other hand, these cells are critically important target and 
effector cells in the pathogenesis of renal diseases (Sterzel et al., 1992, 
Pfeilschifter, 1986; Pfeilschifter, 1994). 
As active part of the inflammatory response to glomerular injury, mesangial cells 
become self-competent to synthesis bioactive molecules like eicosanoids, nitric 
oxide, growth factors and inflammatory chemokines and cytokines. Reactive 
oxygen species have been thought to be produced by mesangial cells in response 
to hyperglycemia and increased levels of prostaglandins are characteristics of 
diabetic and other  glomerulopathies. The role of mesangial cells in the generation 
of eicosanoids and propagation of inflammation has been extensively studied by 
several groups using mesangial cells derived from rats. However, the 
understanding of functions including lipid digestion and metabolism in various 
physiological and pathological conditions is complex and has been difficult to clarify. 
      
1.6    Primary culture of rat hepatocytes 
 
Primary culture of hepatocytes can easily be established from suspensions of 
hepatocytes as demonstrated by Bissell et al. (1973). Since then, this model has 
been used in several pharmacological and toxicological studies. The system of 
primary culture of hepatocytes is also suitable for metabolic studies, since surviving 
for several days keeps the DNA content stable, maintaining specific and unspecific 
enzyme activities at a reasonable level and being able to perform metabolic                                                                                                                            I. Introduction  
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functions, which are specific for the liver (Page, 1979; Dich  et al., 1988; Van Auken 
et al., 1996; Blumberg et al., 1998).  
As the liver plays pivotal roles in a large number of metabolic and immune 
processes, this model has attracted numerous investigations from many 
laboratories.  It has been shown that primary hepatocytes of different species have 
the capacity to produce an acute-phase response on treatment with inflammatory 
mediators such as the cytokines IL-6, IL-1 and TNFα (Bauer et al., 1991). Using 
primary rat hepatocytes, many groups have examined the effects of interferons, 
cytokines, and lipopolysacchride on the release of NO via induction of iNOS (Geller 
et al., 1993; Sewer and Morgan, 1997), or AA metabolites. Such reactions in the 
liver are believed to be a critical  for energy metabolism in endotoxin shock (Kitano 
et al., 2002) or hepatocellular dysfunction (Wang et al., 1993; Prabha et al., 1991). 
Thus, the primary culture of hepatocytes can be efficiently used in the investigation 
of the potential roles of many factors and enzymes, which are important for liver 
function and survival.  
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1.7    Aim of this thesis 
 
This thesis focuses on the regulation of CPT-Iα as an important fatty acid oxidation 
enzyme, in rat glomerular mesangial and liver cells as model systems.  
The main aim was  to investigate CPT-Iα regulation under inflammatory conditions 
in particular, I wanted to analyse whether inflammatory agents or conditions such 
as nitric oxide, cytokines, exogenous sPLA2s or hypoxia have an effect on CPT-Iα 
expression. Moreover, I performed preliminary studies on the regulation of 
 mHMG-CoA synthase, which is another key enzyme of ketogenesis.    
From the results of these studies, I would  propose that under different inflammatory 
conditions, changes in CPT-Iα expression enable the cell to adapt, in order to 
withstand these adverse conditions.  
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   II 
Materials and Methods 
___________________________________ 
2.1 Materials 
 
2.1.1 Chemicals 
 
Acrylamide/bisacrylamide-solutions Roth,  Karlsruhe 
Agar  Gibco Life Technologies, Eggenstein 
Agarose Biozym,  Oldendorf 
Ammoniumpersulfate Sigma  Biochemicals,  Deisenhofen 
Ampicillin Sigma  Biochemicals,  Deisenhofen 
Aprotinin   Roche Biochemicals, Mannheim 
Boric acid   Merk, Darmstadt 
Bovine serum albumin, fatty acid free   Sigma Biochemicals, Deisenhofen; 
5-Bromo-4-chloro-3-indolyl-β-D-galactoside  Roth, Karlsruhe 
Bromphenolblue Serva 
Cell culture media  Gibco Life Technologies, Eggenstein 
Cesium chloride  Merck, Darmstadt 
Cobalt Chloride  Sigma Biochemicals, Deisenhofen 
Coommassie-Brillant-Blue G250  Sigma Biochemicals, Deisenhofen 
cycloheximide Sigma  Biochemicals,  Deisenhofen 
Deferoxamine Mesylate  Sigma Biochemicals, Deisenhofen 
DETA-NONOate Alexis  Biochemicals,  Grünberg 
Diethylpyrocarbonate  (DEPC)  Sigma Biochemicals, Deisenhofen 
Dithiothreitol (DTT)  Sigma Biochemicals, Deisenhofen 
Dulbecco´s modified Eagles medium   Gibco, Berlin 
Dimethylsulphoxide (DMSO)  Merck, Darmstadt 
EDTA Sigma  Biochemicals,  Deisenhofen 
EGTA Sigma  Biochemicals,  Deisenhofen 
Ethrane (enfluran)   Abbott, Wiesbaden 
Ethidium bromide  Sigma Biochemicals, Deisenhofen 
Fetal calf serum (FCS)  Gibco Life Technologies, Eggenstein 
Glycerol Roth,  Karlsruhe II. Materials and Methods 
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HEPES    Roth, Karlsruhe 
Isopropylthiogalactopyranoside (IPTG)  Roth, Karlsruhe 
Leupeptin Roche  Biochemicals,  Mannheim 
Loading Day Solution 6x  MBI Fermentas 
Magnesium sulfate heptahydrate  Sigma Biochemicals, Deisenhofen 
β-Mercaptoethanol  Sigma Biochemicals, Deisenhofen 
Molecular weight markers (DNA) 1 kb/100 bp MBI Fermentas, St. Leon-Rot 
Molecular weight markers (protein)  Amersham Pharmacia, Braunschweig; 
Nicotinamide   Sigma Biochemicals, Deisenhofen 
NZY BROTH  Gibco, Berlin 
Nucleotide triphosphates  Applied Biosystems Applera, Weiterstadt 
1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one 
(ODQ) 
Alexis Biochemicals, Lausen 
Oligonucleotides   Roth, Karlsrue 
Gibco Life Technologies, Karlsruhe 
PD 98059  Calbiochem, 
Penicillin/Streptomycin Gibco,  Berlin 
Peptone  Gibco Life Technologies, Eggenstein 
Phenol/Chloroform Roth,  Karlsruhe 
Phenylmethylsulfulfonylfluoride (PMSF)  Roth, Karlsruhe 
Phosphate buffered saline  Gibco, Berlin 
PIPES   Sigma Biochemicals, Deisenhofen 
Ponceau S  Sigma Biochemicals, Deisenhofen 
Potassium acetate  Merck, Darmstadt 
Potassium phosphate monobasic  Sigma Biochemicals, Deisenhofen 
Potassium chloride  Roth, Karlsruhe 
Roti Load1  Roth, Karlsruhe 
Sodium Dodecylsulfate (SDS)  Merck, Darmstadt 
SNAP Alexis,  Grünberg 
Sodium acetate  Merk, Darmstadt 
Sodium bicarbonate  Sigma Biochemicals, Deisenhofen 
Sodium butyrate  Sigma Biochemicals, Deisenhofen 
Sodium chloride  Merck, Darmstadt 
Sodium citrate  Merck, Darmstadt 
Sodium  fluoride  Sigma Biochemicals, Deisenhofen 
Sodium orthovanadate  Sigma Biochemicals, Deisenhofen 
Sodium phosphate dibasic dodecahydrate  Sigma Biochemicals, Deisenhofen II. Materials and Methods 
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Sulfanilamide Sigma  Biochemicals,  Deisenhofen 
Template suppression reagent (TSR)  Applied Biosystems Applera, Weiterstadt 
Tetramethylethylendiamine (TEMED) Sigma  Biochemicals,  Deisenhofen 
TRI REAGENT  Sigma Biochemicals, Deisenhofen 
Triton X-100  Sigma Biochemicals, Deisenhofen 
Trypan blue   Gibco Life Technologies, Eggenstein 
Trypsin/EDTA Gibco,  Berlin 
Trypsin Inhibitor  Serva 
Tryptone   Gibco Life Technologies, Eggenstein 
Tween 20  Sigma Biochemicals, Deisenhofen 
Ultroser G  BioSepra, Ciphergen 
U0126 Calbiochem,  Schwalbach 
WY 14.643  Sigma Biochemicals, Deisenhofen 
3-(5'-Hydroxymethyl-2'-furyl)-1-
benzylindazole (YC-1) 
Alexis Biochemicals, Lausen 
Yeast extract  Gibco Life Technologies, Eggenstein 
Xgal Roth,  Karlsruhe 
 
Acetone, chloroform, ethanol, ether, methanol, isopropanol, acids and all other, not listed 
chemicals were supplied from Merck (Darmstadt), Roth (Karlsruhe) or Sigma Biochemicals 
(Deisenhofen). 
 
Other materials and kits 
 
Deoxynucleoside Triphosphate Set  Roche Biochemicals, Mannheim 
ECL Detection Kit/Films  Amersham Pharmacia, Freiburg 
Effectene Transfection Reagent   Qiagen, Hilden 
Endofree Plasmid Maxi Kit (Qiagen-tip 500)  Qiagen, Hilden 
Dual-Luciferase Reporter Assay System  Promega, Mannheim 
Immobilon-P Transfer Membrane  Millipore, Eschborn 
Kodak BioMax MR-1 Scientific Imaging Film Kodak-Industrie,  Chalon-sur-Saone 
NucleoBond PC 100 Kit (AX 100)  Macherey & Nagel, Düren  
NucleoSpin Extract 2 in 1  Macherey & Nagel, Düren 
Penicillin/Streptomycin (10.000 U/ml /10.000 µg/ml )  Gibco, Berlin  
Phosphate buffered saline  Gibco, Berlin 
Stericup MILLIPORE  Millipore Carporation, Bedford 
SuperScript II, Rnase H, Reverse Transcriptase  Invitrogen, II. Materials and Methods 
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TOPO TA Cloning Kit  Invitrogen, Groningen (Netherlands) 
Transwell-Clear inserts 6-well polystyrene-plates  Costar, Bodenheim 
QIAGEN filter Plasmid Midi/Maxi Kit   Qiagen, Hilden 
QIAGEN Plasmid Mini Kit  Qiagen, Hilden 
 
 
 2.1.2     Media, buffers and solutions 
2.1.2.1     Immunoblot-analysis 
 
4x Laemmli-buffer   125   mM 
10     % 
50    mM 
40    % 
0.01 % 
Tris/HCl pH 6.8 
(w/v) SDS 
Dithiothreitol 
(v/v) Glycerol 
(w/v) Bromphenol blue 
10x PAGE  250  mM 
1      % 
520  mM 
Tris 
(w/v) SDS 
Glycin 
TBS Tris-buffered saline 
10xsolution 
50    M 
150  M 
Tris pH 8.0 
NaCl 
pH 7.4 
Transfer buffer  25    mM 
192  mM 
20    % 
Tris 
 Glycine pH 8.3   
 (v/v) Methanol 
Triton-X100 lysis-buffer 
(supplemented with protease 
inhibitor's mix) 
20    mM 
1      mM 
1      mM 
2      mM 
1       % 
Tris/HCl pH 7.6 
EDTA 
EGTA 
DTT 
Triton X-100 
Protease inhibitor's mix  2       µg/ml 
10     µg/ml  
2       µg/ml 
1       mM 
2       µg/ml 
1       mM 
1       mM 
 Aprotinin 
 Leupeptin 
 Pepstatin A 
 PMSF 
 Trypsin inhibitor 
 NaVO4 
 NaF 
Protein molecular weight marker 
(MBI Fermentas) 
5       µl   per well II. Materials and Methods 
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Coomassie staining solution  2.5        g/l 
40          % 
10          % 
50          %  
Coomassie Brilliant Blue R 250 
methanol 
glacial acetic acid  
water 
Destaining solution  40          % 
10          % 
50          % 
methanol 
glacial acetic acid 
water  
 
2.1.2.2   Buffers and solutions for cell culture 
      Media  for mesangial cell culture 
RPMI medium   
10     %             
 5      ng/ml       
 5      ml            
 5    ml           
RPMI (Gibco) 
FCS  
Insulin 
Penicillin/Streptomycin 
Trypsin/EDTA 
DMEM medium   
0.1     mg/ml 
5        ml 
5        ml 
DMEM (Gibco) 
Fatty acid free BSA 
Penicillin/Streptomycin 
Trypsin/EDTA 
 
 
Buffers and media  for primary culture of rat hepatocytes  
  
Ultroser G solution  
(must be used immediately) 
For 500 ml Dulbecco's MEM (Gibco) 
 
The flask content ( BioSepra ) was solubilised by gentle 
shaking in 20 ml DMEM  
and put back to the rest of the medium under sterile 
conditions 
 
10 X Buffer concentrate  For final volume of 1.2 litre : 
98.16       g                NaCl 
4.4           g                 KCl 
2.4           g                 MgSO4 x7 H2O 
11.4         g                 Na2HPO4 X 12 H2O 
0.64         g                 KH2PO4 
Volume adjusted to  1200 ml with H2O  II. Materials and Methods 
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EDTA perfusion buffer  For final volume of 1 litre : 
 
100             ml                10 X Buffer concentrate    
                                        (see above)         
750             mg               EDTA 
2.1              g                  NaHCO3 
200             U/ml             Penicilin 
200             µg/ml           Streptomycin 
Volume adjusted to 1 litre with H2O 
pH adjusted to 7.4 with 1M HCl 
sterilised by filtrating (Stericup MILLIPORE) 
 
Collagenase perfusion  
buffer A 
For final volume of 1 litre : 
100              ml               10 X Buffer concentrate 
 0.5              g                  CaCl2 
Volume adjusted to 1 litre with H2O 
pH adjusted to 7.4 with 1 M HCl 
sterilised by filtrating ( Stericup MILLIPORE ) 
 
Collagenase perfusion buffer 
(for a cell isolation from one rat 
liver; must be used immediately) 
For final volume of 0.2 litre: 
200       mg         collagenase H  
20         ml          collagenase perfusion buffer A 
sterilised by  filtrating using sterilising membrane of 
0.22 µm pore diameter. 
Volume adjusted to 200 ml with Collagenase perfusion 
buffer A 
4         ml                Penicillin/Streptomycin            
 
DMEM medium for cell 
isolation 
Dulbecco's MEM (Gibco) 500 ml: 
10        ml              Penicillin/ Streptomycin 
 
DMEM medium for cell 
incubation 
Dulbecco's MEM (Gibco) 500 ml: 
 4        %               Ultroser G (20 ml Ultroser  
                             solution) 
 5        ml               Penicillin/ Streptomycin 
 1        mmol/l        NAD  
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2.1.2.3    Media for bacteria culture and agar plates  
 
 
LB medium (sterilised) 
 
21       g           NZY BROTH  
Volume adjusted to 1 litre with H2O 
SOC medium   Invitrogen, Groningen (Netherlands) 
 
2xYT Medium  in  900ml of H2O dissolved:  
16     gr               bacto-tryptone  
10     gr               bacto-yeast extract  
 5      gr               NaCL  
pH adjusted to 7.0 with 1M HCL 
Volume adjusted to 1 litre with H2O 
 
Agar plates  For final volume of 100 ml: 
0.7       g           NZY BROTH 
1.5       %          Agar 
sterilised by autoclaving 
 
CaCl2 Solution  60       mM           CaCl2 
15       %              glycerol 
10       mM           PIPES 
sterilised by autoclaving 
 
       
 
2.1.2.4  Additional buffers and solutions 
 
Ampicillin  50 mg/ml  stock solution 
sterilised by filtrating 
 
10 x PBS (pH 7.4)  1.3         M                  NaCl 
30          mM               NaH2PO4 
70          mM               Na2HPO4 
TAE (Tris/acetate/EDTA) electrophoresis 
buffer 
50 x stock solution, 1 litter 
2            M                  Tris 
1            M                  Acetic acid 
50          mM               EDTA II. Materials and Methods 
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TBE (Tris/borate/EDTA) electrophoresis 
buffer 
10x stock solution, 1 litter 
10           g                   Tris base (890 mM) 
55           g                   Boric acid (890 mM) 
40           ml                 0.5 M EDTA , pH 8.0  
TE-buffer   10          mM               Tris (pH 8.0)  
1            mM               EDTA  (pH 8.0) 
 
2.1.2.5   DEPC-treatment 
Solutions for RNA based methods were treated with diethyl pyrocarbonate (DEPC) to 
inactivate RN ases. DEPC-treated water was obtained by adding 1 ml DEPC per liter of 
distilled H2O.  After mixing in an overnight step at RT, the solution was autoclaved. 
 
2.1.3  Enzymes 
 
Collagenase H  Roche Diagnostics, Mannheim 
Turbo Pfu/Pfu-DNA Polymerase  Stratagene, Heidelberg 
Proteinase K  Roche Biochemicals, Mannheim 
Restriction Enzymes  NEB, Frankfurt a.M.; 
MBI-Fermentas, St. Leon-Rot 
Reverse Transcriptase  Invitrogen, Karlsruhe 
Taq-DNA polymerase  Applied Biosystems Applera, Weiterstadt 
 
 
2.1.3.1      sPLA2's used for treatment  
 
Abbreviation  
 
Type Source  Supplier 
WT-IB Wild-type  porcine  sPLA2-IB Porcine 
pancreas  
Sigma 
IB-H48Q  Catalytically inactive porcine 
sPLA2-IB mutant 
Recombinant  provided by Dr. M. J. 
W. Janssen 
(Literaturstelle 
angeben: Beck et al ., 
2003) 
hIIA  Wild-type human sPLA2-IIA   Recombinant  provided by Prof. 
Tibes, Roche 
Diagnostics, 
Germany  II. Materials and Methods 
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hIIA-H48N  Mutant human sPLA2-IIA   Recombinant  provided by Dr.  
D.C. Wilton  
Rat-IIA   Rat sPLA2-IIA   Recombinant  provided by Dr.  
G. Lambeau  
Bee Bee  venom  sPLA2 Bee  venom  Sigma   
Naja  Snake venom sPLA2  N. mossambica 
mossambica 
Sigma 
OS1 Snake  venom  sPLA2  O. scutellatus 
sc. 
provided by Dr.  
G. Lambeau 
OS2 Snake  venom  sPLA2  O. scutellatus 
sc. 
provided by Dr.  
G. Lambeau 
 
 2.1.3.2   Pretreatment of enzymes  
 
Proteinase K 
The lyophilized enzyme (10 mg/ml) was dissolved in distilled H2O, incubated for 30 min at 
37°C and aliquoted. The aliquots were stored at –20°C until use. 
 
RNase A 
RNase A was dissolved to a final concentration of 10 mg/ml in RNase-buffer [Tris/HCl (10 
mM, pH 7.5), NaCl (15 mM)]. The enzyme solution was incubated for 30 min at 95°C and 
cooled to room temperature overnight. Aliquots were stored at –20°C until use. 
 
2.1.4     Antibodies and antiserum 
 
Anti-a-actin (mouse monoclonal)  Sigma Aldrich Fine chemicals 
Anti-β−tubulin (D-10) IgG  (mouse, 
monoclonal)  
Santa Cruz Biotechnologies, Heidelberg 
Anti-mouse IgG (horseraddish-peroxidase 
coupled) 
Santa Cruz Biotechnologies, Heidelberg 
Anti-rabbit IgG (horseraddish-peroxidase 
coupled) 
Santa Cruz Biotechnologies, Heidelberg 
Anti-CPT-Iα IgG (rabbit, polyclonal)  provided by Prof. Pfeilschifter 
Anti-rat sPLA2-IIA  provided by Prof. Van den Bosch 
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2.1.5  Proteins 
 
Collagen from calf skin  Sigma, Deisenhofen 
IL-1β  Cell Concepts, Umkirch, Germany 
TNFα  Knoll AG, Ludwigshafen, Germany 
 
2.1.6   Plasmids 
 
2.1.6.1   Vectors   
pCR II TOPO  Invitrogen, Groningen ( Netherlands ) 
pGL3-Basic Vector  Promega, Mannheim 
 
2.1.6.2   Constructs  of  CPT-Iα promoter luciferase vectors   
pGL3 + rat CPT-Iα Prom Frag 1  Nucleotides 
-4495/+1240 
provided by Dr. Edwards A. 
Park 
 
pGL3 + rat  CPT-Iα Prom Frag 2
 
Nucleotides 
-4495/+19 
 Park , at al., 1998; 
Jansen M, at al., 2000 ) 
    
PGL3 + rat CPT-Iα Prom Frag 3  Nucleotides 
  -210/+19 
see 2.2.4 
 
2.1.7   Bacterial strains 
 
    Genotype 
E.coli XL-1 blue  Stratagene, Heidelberg  supE44 hsdR17 recA1 endA1 
gyrA46thi relA1 lac
- F`[proAB
+ lacI
q 
lacZ∆M15 Tn10(tet
r)]   
TOP 10  Invitrogen,  
Groningen ( Netherlands ) 
F
- mcrA ∆(mrr-hsdRMS-
mcrBC)Φ80lacZ ∆M15 ∆lacX74 
recA1 deoR araD139 ∆(araleu)7697 
galU galK rpsL (Str
R) endA nupG 
 
2.1.8 Cell  culture   
 
primary rat liver cells 
 
preparation see 2.2.2.2 
Rat Mesangial Cell (rMC),   
Eukaryotic cell line  
preparation of primary cells from rat kidney by Prof. 
Pfeilschifter, pharmazentrum frankfurt II. Materials and Methods 
 
  26
2.1.9   Oligonucleotides 
 
2.1.9.1   Cloning  of  CPT-Iα Promoter-Fragment 3 
Fragment   Forward Primer  
( Sac I ) 
Reverse Primer  
PGL3 + rat CPT-Iα Prom 
Frag 3  
CGAGCTCACAAGGTAA
GGAATGC 
pGL3 Basic rev primer 
 
2.1.9.2   Semiquantitative  PCR 
  Fragment size (bp) Sequence 5’ ⇒ 3’ 
GAPDH for  ACC ACA GTC CAT GCC ATC AC 
GAPDH rev 
 
452  TCC ACC ACC CTG TTG CTG TA 
CPT-Iα  for  ATG ACG GCT ATG GTG TCT CC 
CPT-Iα  rev 
 
124  GTG AGG CCA AAC AAC AAG GTG AT 
mHMG-CoAs for   CCT CTG GAG AAG CTG GTG TC 
mHMG-CoAs rev 
 
154  GTA CCA AGT GCC TGG GAA GA 
 
2.1.9.3   Sequencing  primer 
  Sequence 5’ ⇒ 3’ 
pGL3 Basic for  CTA GCA AAA TAG GCT GTC CC 
pGL3 Basic rev  CTT TAT GTT TTT GGC GTC TTC CA 
 
2.1.10  Laboratory equipment 
 
ABI-Prism 310 Genetic Analyser  Applied Biosystems Applera, Weiterstadt 
Recirculating recirculating apparatus 
Minipuls 3 
Gilson ABIMED 
Gel dryer 583  Bio-Rad, München 
GeneAmp 2400/9600 Thermocycler  Applied Biosystems Applera, Weiterstadt 
Gene Quant II  Amersham Pharmacia, Braunschweig 
Herasafe clean bench  Heraeus, Hanau 
Hyperprocessor Amersham  Pharmacia,  Braunschweig 
Incubator Heraeus BBD 6220  Heraeus, Hanau 
AutoLumat LB953  Berthold, Pforzheim 
Microplate reader Benchmark  Bio-Rad, München 
PhosphoImager BAS 1500  Raytest, Straubenhardt II. Materials and Methods 
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2.1.11  Computer software 
 
DNA/Protein homology search  BLAST search (National Center of 
Biotechnology, USA; URL: 
http://www.ncbi.nlm.nih.gov); 
Graphic processing  Corel Draw 8.0/10.0 
Presentations Powerpoint  2000 
Statistical analysis  Sigma Plot 4.0 (Students T-Test) 
Microsoft Excel 2000 
Text processing  Microsoft Word 2000 
 
 
Programs belonging to special devices are mentioned separately in the appropriate 
sections. 
2.2   Methods 
 
2.2.1  Microbiologic methods 
 
2.2.1.1   Bacterial  culture 
The E. coli XL1-blue strain (Stratagene) was used for amplification of plasmid DNA. The 
strain was either grown in liquid LB (Lauria-Bertani) or SOC medium (2.1.2). For selection, 
the media contained ampicillin (50 µg/ml). Agar plates were generated with LB-ampicillin 
medium supplemented with agar (15 g/l). For long-term preservation of transformed 
bacteria, cells were mixed with sterile glycerol [30% (v/v)] and stored at –80°C. 
 
2.2.1.2      Competent bacteria for transformation 
To yield high transformation efficiencies from plasmid DNA in bacteria, cells have to be 
pretreated chemically. LB-Medium 250 ml was inoculated with 200 µl of an overnight 
bacterial E. coli culture and grown at 37°C until the suspension reached an optical density 
of 0.5 (OD600 nm). The bacterial growth was stopped by incubating the suspension for 5-10 
min on ice. Bacterial cells were concentrated by centrifugation (15 min, 4300 rpm, 4°C). 
The cellular pellet was subsequently resuspended in 80 ml of ice-cold CaCl2 solution, 
mixed and incubated on ice for 10 min. The bacterial suspension was centrifuged again (15 
min, 4300 rpm, 4°C), subsequently the pellet was gently resuspended in 20 ml of ice-cold 
CaCl2 solution and incubated on ice for additional 20 min. Thereafter, aliquots of competent 
bacteria were frozen immediately in liquid nitrogen and stored at –80°C. II. Materials and Methods 
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2.2.1.3   Transformation 
A competent bacteria suspension (100 µl) was thawed on ice and incubated with 5 µl of 
plasmid or DNA solution. The bacteria/DNA mixture remained on ice for additional 30 min 
followed by an incubation at 42°C for 1 min. The bacteria were chilled on ice again for 2 
min, before 300 µl of SOC-medium was added and for initial expression of the plasmid, 
bacteria were incubated for 1 h at 37°C on a shaker. The plasmid encodes an ampicillin-
resistance gene. Therefore, bacterial cells, which take up the plasmid genome and become 
ampicillin resistant. 20 - 200 µl of this transformation solution was spotted in the centre of 
prewarmed agar plates  (37°C) containing ampicillin. 
To enable a blue/white screening for recombinant clones ( pCR TOPO), the agar plate was 
supplemented with 50 µl X-Gal (2% in DMSO) and 50 µl IPTG (0.1 M in distilled H2O). The 
plates were incubated overnight at 37°C. 
 
2.2.2    Cell biological methods 
 
2.2.2.1    Cultivation of rat mesangial cells 
Rat mesangial cells were grown in RPMI 1640 supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin, 25 mM HEPES and 10% heat-inactivated FCS (GIBCO-BRL, 
Eggenstein, Germany).  
Mesangial cells were cultured at 37°C in a humidified atmosphere containing 5% CO2 
(Heraeus BBD 6220 incubator). For passaging, cells were washed twice in phosphate 
buffered saline (PBS), subsequently trypsinised (Trypsin, EDTA) and diluted in a 1:20 ratio 
with RPMI. After trypsinisation, cells were concentrated (5 min at 1100 rpm, Heraeus 
Megafuge 1.0, rotor 75750F) and diluted in RPMI medium. Thereafter, mesangial cells 
were seeded into culture plates (Greiner) and maintained in RPMI medium. 
For long-term storage, the cells were treated as follows: after trypsinisation, cells were 
concentrated, diluted in freezing medium (growth medium supplemented with 10% DMSO) 
and stored in cryotubes (Nunc). The cryotubes were cooled down slowly overnight to –
70°C and finally stored in liquid nitrogen. 
 For stimulation, mesangial cells were stimulated in DMEM, supplemented with 100 U/ml 
penicillin, 100 µg/ml streptomycin and bovine serum albumine (BSA), instead of RPMI 
medium.  
 
2.2.2.2    Isolation and primary culture of adult rat hepatocytes   
Prefasted adult male Sprague-Dawley rats with 250-300 g body weight were used for 
isolation of primary rat hepatocytes. The animals were fed standard rat laboratory diet, had II. Materials and Methods 
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access to water and were kept in a temperature- and light-controlled room. Isolated 
hepatocytes were prepared according to a EDTA/collagenase protocol (Seglen, 1976). This 
method is widely used experimentally for the isolation of many different cell types from 
animal organs and tissues. Briefly, the rats were anaesthesised with enfluran. After 
cannulation of the portal vein, perfusion was carried out with a recirculating perfusion 
apparatus as follows.  
First, the liver was perfused with  ice-cold EDTA buffer (2.1.2.2.2) at a rate of 30 ml/min for 
5 min. Then, the cannulated rat liver was taken out and placed in sterilised glass on ice and  
the perfusion was continued for another 5 min. The next perfusion steps were performed in 
an oxygen saturated environment by gassing with 100% O2. The cannulated liver was 
transferred into a new sterilised glass at RT and  perfused at  a maximum rate of 37 ml/min 
for 10 min with the same  EDTA buffer prewarmed at 37°C. These steps were required for 
the dissolving of the desmosome (cellular junction) by withdrawing Ca
2+ from tissue via  
EDTA chelation of this ion.  
Finally, the liver was perfused with collagenase buffer at 37°C at a rate of 20 ml/min for 
another 15 min. The Ca
2+  activated collagenase digested the extracellular matrix and 
thereby caused release of cells from the tissue.  
After the liver was disconnected  from perfusion apparatus and transferred to Petri dishes, 
the cells were separated by gentle scraping with a spatula. The cellular suspension was 
filtered through a gauze, washed with 300 ml DMEM + 2% Pen/Strep buffer, and intact 
hepatocytes were separated from other cells such as fibroblasts and astrocytes, by low 
speed centrifugation (500 rpm, Heraeus Megafuge 1.0, rotor 75750F)  at RT for 3 min. The 
pellets were washed in 200 ml DMEM + 2% Pen/Strep buffer, centrifuged at 1500 rpm for 
10 min at RT, and the cell pellet was resuspended in DMEM incubation medium (2.1.2.2.2) 
to a concentration of 5 X 10
5 cells/ml. Hepatocytes were placed in six well plates (3 ml/well) 
and incubated for 16 hr. Experiments were performed thereafter.  
 
2.2.2.3 Reporter gene assays 
The regulation of gene expression was examined using a reporter-gene-assay. For this 
purpose, DNA sequences carrying putative regulatory elements were cloned in front of a 
reporter gene, in this case the gene encoded the luciferase enzyme. Newly generated 
constructs were transferred into the eukaryotic target cells by liposomal transfection. 
Thereafter, transfected cells were stimulated with the compounds to be tested. After 
transfection and stimulation, cells were harvested to measure the amount of synthesized 
reporter gene products. To assess the influence of different agents  on CPT-Iα gene 
regulation, reporter gene expression in stimulated cells and unstimulated cells were 
compared. Each transfection was conducted threefold and repeated four to six times. No 
reporter gene products were synthesized when cells were transfected with empty vector.  II. Materials and Methods 
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.2.2.4  Transfection of mesangial cells with luciferase constructs 
Confluent mesangial cell cultures were trypsinized and cultured in fresh medium. The cells 
were seeded in 2 ml RPMI medium per well onto 6-well-culture-plates and incubated for 18 
- 24 h under standard conditions. The cells should have reached a confluency of about 60 - 
80%. After the cells were washed with PBS, 1.6 ml DMEM/0.01 % BSA was added per well 
and cells were incubated at 37°C while Effectene Transfection Reagent (Qiagen, Hilden) 
was prepared. Although this preparation was done according to the manufacturer's 
instructions, some transfection conditions had to be optimized for the mesangial cell line. 
The volume of all medium used here is given per well of 6-well plate. Meanwhile, 400 ng of 
Plasmid DNA (CPT-Iα promoter luciferase expression construct, dissolved in TE, pH 7.4) 
plus 40 ng Renila-luciferase-DNA were diluted with 100 µl of DNA-condensation buffer (EC 
Buffer). After adding 3.2 µl Enhancer, the DNA mixture was thoroughly mixed for 1 min and 
incubated for 5 min at RT. Afterwards, 10 µl Effectene was supplemented to the DNA-
Enhancer solution, mixed by pipetting and incubated for 10 min at RT. The transfection 
complex was diluted in 600 µl DMEM medium, and 713 µl of this solution was immediately 
added drop-wise onto the cells. 
 Cells were washed with PBS after transfection (16 h) and maintained in 1.5 ml of fresh 
DMEM. Subsequently, mesangial cells were either unstimulated (negative control) or 
stimulated with the substances to be tested.  
Then, cells were washed with ice-cold PBS, lysed in 200 µl lysis buffer from the Dual-
Luciferase Reporter Assay System (Promega), and scraped with a rubber policeman into 
1.5-ml tubes. The cell lysates were subjected to a freeze/thaw cycle to complete lysis of 
cells. After short centrifugation, the assays for firefly luciferase activity and Renilla 
luciferase activity (transfection control) were performed sequentially using a luminometer 
(Autolumat; Berthold, Wildbad, Germany). Values for the CPT-Iα promoter activity were 
divided by those obtained for Renilla-luciferase activity.  
 
2.2.2.5 Luciferase assay 
The luciferase of the firefly (Photinus pyralis) catalyses the oxidation of luciferin. During this 
reaction, photons are released at a wavelength of 562 nm. A quantitative measurement of 
the emitted light was performed by employing a luminometer (AutoLumat LB953, Berthold). 
Cells were transiently transfected with a luciferase-construct, stimulated and harvested in 
1x Reporter-Lysisbuffer (Promega) as described by the manufacturer. The solutions 
needed for measurement were prewarmed at RT and 20 µl of cell-extract were pipetted  in 
a polystyrene-tube. The reaction was started in the Luminometer by injection of 100 µl 
Luciferase-Assay-Reagent (Promega) (20 mM Tricin, 1.07 mM (MgCO3)Mg(OH)2 x 5 H20, 
2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 µM Coenzym A, 470 µM Luciferin, II. Materials and Methods 
 
  31
530 µM ATP pH 7.8) followed by injection of Renilla-Assay Reagent (Promega). The 
emitted light was measured for 10 s with a Photomultiplier and expressed in Relative Light 
Units short (RLUs) by the luminometer. Values for the CPT-Iα promoter activity were 
divided by those obtained for Renilla liciferase activity. Values obtained with treated cells 
were expressed as x-fold increase in luciferase activity compared  to control. 
 
2.2.3  Measurement of cell parameters 
 
2.2.3.1    Nitric oxide synthase activity: Griess assay 
Nitrite (NO2
-) is a stable NO oxidation product, which can be evaluated as a direct readout 
for nitric oxide synthase activity using the Griess-assay as described (Mühl et al., 1997). 
The lowest detection limit for nitrite in this assay is 1.5 µM. 
Cell culture supernatants were cleared by centrifugation (5 min at 400 g). 200 µl of 
supernatants were mixed with an equal volume of ready-to-use Griess Reagent (Roche, 
Mannheim). After 5 min at room temperature, the absorbance was measured at 540 nm 
with a reference wavelength at 690 nm. 
 
2.2.3. 2    Viability of the primary rat liver cell culture  
The rat primary liver cell number and viability of the suspension after their isolation (2.2.2.2)   
was assessed  by trypan blue exclusion. Trypan blue (50 µL) was mixed with 50 µl cell 
suspension and the number of viable cells, i.e. those cells which were not stained with 
trypan blue, were determined microscopically. Primary cell cultures which had a viability of 
more than 80% were used for the experiments.  
 
2.2.4      Molecular biology methods 
 
2.2.4.1    Reverse transcriptase reaction (RT) 
The enzyme SuperScript
tmII RNase H
- Reverse Transcriptase is purified from E.coli 
containing the pol gene of Moloney Murine Leukemia Virus. The enzyme synthesizes a 
first-strand complementary DNA  (cDNA) strand using RNA as a template.  
First, an Oligo dT primer mRNA is hybridised to a poly (A) tail of isolated mRNA. Then, in 
the next reaction the reverse transcriptase extends this primer to yield  cDNA. Finally, the 
RNase H-treatment removed the RNA strand. 
Reverse transcriptase reaction: 
1-5            µg             total RNA 
1               µl              oligo (dT) 
DEPC water was  added  to a total volume of 12 µl. II. Materials and Methods 
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The mix was heated to 65°C for 5 min and then incubated on ice for 10 min.  
 
To the oligo (dT) hybridisation mix, the following components were added: 
4              µl              5 X first-Standard Buffer 
2              µl              0.1 M   DTT 
2              µl              10 mM dNTP mix (10 mM each dATP, dGTP, dCTP and dTTP) 
1              µl               Reverse Transcriptase 
The mix  was incubated first for 50 min at 42°C and afterward for 15 min at 70°C. Aliquots 
of the cDNAs were stored at 4°C. 
2 µl of the synthesised cDNA was used as a template for amplification in the Polymerase 
Chain Reaction (PCR).  
 
2.2.4.2   Polymerase chain reaction (PCR)  
This method enables the in vitro amplification of DNA fragments without time consuming 
cloning and identification steps. The method is based on the availability of heat-stable DNA 
polymerases which allow multiple denaturation of template DNA, annealing of driver 
sequences (primer) and synthesis of DNA by amplification steps within one tube. 
Polymerase chain reaction: 
2 µl  RT-product (2.2.3.2) or 
X  µl          Plasmid-DNA Template (50-100 ng) 
5         µl         10x PCR-Buffer 
1         µl          10 mM dNTP mix (10 mM each dATP, dGTP, dCTP and dTTP) 
1         µl          Forward/Reverse Primer-Mix (10 µM)  
0.5      µl          Taq- Polymerase (1 U/µl) 
Water was  added  to give a total volume of 50 µl 
The reaction was performed in a thermocycler (GeneAmp 2400 or 9600, PE Biosystems). 
Conditions varied depending on the gene of interest, the type of  polymerase used for 
amplification and the experimental set up. For semi-quantitative gene analysis Taq DNA  
polymerase which was originally isolated from thermophilic eubacterium Thermus 
aquaticus was used. This enzyme exhibits highest activity at 75°C and is stable against 
incubations at elevated temperatures (95°C). In general, 23-30 cycles of the following steps 
were carried out: 1 min 94°C, 1 min e.g. 60°C (primer-annealing) and 2 min 72°C 
(elongation). The amplification was completed by a final 7 min incubation step at 72°C. 
Depending on special conditions of template, primers and cell tipe, the protocol was altered 
accordingly (see table below). The samples were stored at 4°C and analyzed by gel 
electrophoresis. 
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Semi-quantitative gene analysis 
for 
Annealing 
temperature  
Cycle number 
GAPDH 55°C  23 
CPT-Iα  51°C  Mesangial cell: 28 
Rat hepatocytes: 32 
mitochondrial 3-hydroxy-3-
methylglutaryl-CoA synthase (mHMG-
CoA synthase) 
55°C  Mesangial cell: 30  
Rat hepatocytes: 28  
 
For amplification of plasmid-DNA, Template taq -polymerase was used. 30–35 cycles were 
sufficient to amplify genomic CPT-Iα promoter fragment 3 using the following PCR 
program: 1 min 94°C, 1 min 53°C and 2 min 72°C. Finally, amplification was completed by 
a 7 min incubation step at 72°C. 
 
 
2.2.4.3      Cloning of PCR products in vector (pCR II TOPO) and   
luciferase vector (pGL3) 
After amplification, PCR product (CPT-Iα promoter fragment 3)  was cloned into the pCR II 
TOPO-Cloning Vector (Invitrogen), and then ligated to the target vector pGL3 (Promega). 
PCR insert in pCR II TOPO was restricted by type II endonucleases (Sac I/ Bgl II) and 
separated from these cloning vectors by gel electrophoresis and subsequent gel elution 
using a column gel extracting kit  (NucleoSpin Extract 2 in 1 by Macherey & Nagel), 
followed by ligation into the prepared luciferase-vector pGL3. These luciferase constructs 
were used to transfect mesangial cells. 
 
 
2.2.4.4     Preparation of plasmid DNA 
Miniprep: Isolation of plasmid DNA was performed using the QIAGEN Plasmid Mini Kit 
according to the manufacturer's instruction. 
Midiprep: Higher amounts of plasmid DNA (expected yields: 75 - 100 µg) were obtained 
using the NucleoBond PC 100 Kit (AX 100) as described by the manufacturer. 
Maxiprep: To obtain endotoxin-free plasmid DNA for transfection experiments, we 
employed Endofree Plasmid Maxi Kit (Qiagen-tip 500) according to the manufacturer’s 
instruction. 
 
2.2.4.5     RNA isolation from cultured cells 
Total RNA isolation was performed with TRI-Reagent according to the protocol from the 
manufacturer (Sigma Biochemicals). All centrifugations were carried out at 13.000 rpm in II. Materials and Methods 
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an Eppendorf centrifuge at 4°C. The cells were washed twice with PBS. The media and 
washing buffer were removed by a pipette tip attached to a vacuum pump. Subsequently, 
cells were lysed with 1 ml of TRI-Reagent. The lysate was transferred into an Eppendorf 
tube. After addition of 200 µl chloroform, the samples were mixed and stored at RT for 10 
min. After centrifugation for 15 min, the upper phase was collected into a fresh tube. 
Precipitation of RNA with 700 µl of isopropanol was carried out overnight at -20°C. The 
precipitated RNA was pelleted by centrifugation for 15 min and then washed with cold 70% 
ethanol (30% DEPC-treated water), followed by centrifugation for 10 min. Subsequently, 
ethanol was carefully removed and the final RNA pellet was dried at 37°C and 
resuspended in a suitable  volume of DEPC-treated water. After a 10 min incubation at 
65°C, the amount of isolated RNA was quantified photometrically (2.2.4.6). 1-2 µg of 
isolated RNA was controlled for integrity by agarose gel electrophoresis (1%, 1x TBE 
buffer). 
 
2.2.4.6     Quantification of nucleic acid concentrations 
Concentrations of nucleic acids were determined photometrically at  260 nm (Gene 
 Quant II, Amersham Pharmacia). The ratio between the readings at 260 nm and 280 nm 
(OD260/OD280) provides an estimation of the purity of the nucleic acid preparation. Highly 
pure DNA or RNA are characterized by ratios between 1.8 and 2.0.  
Low amounts of DNA were estimated by agarose gel electrophoresis (2.2.4.7) in 
comparison with a known standard. 
 
2.2.4.7    Agarose gel electrophoresis of nucleic acids 
Nucleic acids were separated by gel electrophoresis using agarose gels. The agarose 
concentration was dependent on the molecular weight of the analysed nucleic acids. For 
separation of DNA molecules from 0.5 to 2 kbp, usually 1% agarose gels (w/v) were 
employed. Smaller DNA fragments (100 bp – 500 bp) were separated in high density gels 
(1.5 - 2% agarose gels). Agarose (Roth/Gibco Life Siences) was dissolved in 1x TBE gel 
electrophoresis buffer. Ethidium bromide was added to a final concentration of 500 ng/µl. 
Ethidium bromide binds to DNA or RNA by intercalation between the bases and thus 
enables an ultraviolet fluorescence illumination of nucleic acids. The DNA/RNA samples 
were diluted with loading buffer [6x Loading Dye Solution] and loaded onto the gel. 
Electrophoresis was performed in 1x TBE buffer with a voltage of 10 V/cm electrode 
distance. DNA fragment sizes were estimated using molecular weight markers (MBI 
Fermentas).  
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2.2.4.8    DNA isolation from agarose gels 
The use of the NucleoSpin Extract 2 in 1 Kit (Macherey & Nagel) enables a pure extraction 
of DNA fragments directly from agarose gels. The system is based on a silica membrane, 
which binds single and double stranded DNA. The DNA fragments of interest were cut from 
the gel with a razor blade and further processed according to the manufacturer’s 
instructions.  
 
2.2.4.9    Restriction 
Type II endonucleases isolated from bacteria specifically bind palindromic sequences with 
a subsequent cleavage of the DNA molecule at their recognition site. This process 
generates either blunt-end fragments or overhanging cohesive ends, which allow the 
generation of recombinant DNA by enzymatic ligation. The standard approach for DNA 
digestion is subsequently listed. After incubation at the appropriate temperature, DNA 
cleavage was checked by agarose gel electrophoresis (2.2.4.7). 
DNA  Digestion: 
X        µl  DNA (3 µg) target vector 
1.0     µl  10x buffer 
0.5     µl        restriction enzyme (10 U/µl) 
X         µl        H2O :10 µl Total volume 
 
2.2.4.10 Ligation 
Generation of covalent phosphodiester bonds between the 5´-phosphate and the 3´-OH of 
DNA fragments is catalyzed by T4-DNA ligase. The ligation reaction was performed with 
restricted or PCR-amplified DNA. The DNA was separated on an agarose gel. 
Subsequently, the DNA fragment of interest was isolated using a column gel extracting kit 
by Macherey & Nagel. The gel extracted fragment was added to the ligation reaction. The 
mixture was incubated overnight at 16°C. Afterwards, an aliquot of this reaction was 
transformed into competent bacteria as described in section 2.2.1.3. 
 
DNA ligation: 
X  µl  target vector DNA (70 ng) 
X  µl  gel-extracted DNA fragment (130 ng) 
2  µl  5x ligase buffer 
0.5  µl  T4-DNA ligase (1U/µl) 
X µl H2O to total volume of 10 µl  
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2.2.4.11 DNA  sequencing 
DNA sequencing was performed using the ABI-Prism 310 Genetic Analyser (Applied 
Biosystems Applera) based on the dideoxynucleotide chain termination method [Sanger et 
al.,  1977]. In the termination labeling mix, the four dideoxy terminators (ddNTPs) were 
tagged with different fluorescent dyes. This technique allows the simultaneous sequencing 
of all four reactions (A, C, G, T) in one reaction tube. The probes were separated 
electrophoretically using a micro capillary. As each dye terminator emits light at a different 
wavelength when excited by laser light, all four colors corresponding to the four nucleotides 
can be detected and distinguished within a single run. Raw data were evaluated by the Abi 
Prism sequencing analysis software on a Power G3 Macintosh computer. The sequencing 
reaction, as listed in the table, was performed in a thermocycler (GeneAmp 2400, Applied 
Biosystems Applera) with 25 cycles of the following temperature steps: 96°C for 10 sec, 
55°C for 5 sec, 60°C for 2 min. For the detection process, probes were prepared as 
described by the manufacturer. 
 
DNA sequencing:  
 
X   µl  DNA (250 ng plasmid DNA or 50 ng PCR derived DNA) 
2 µg  sequencing  premix 
1  µl  primer (10 µM) 
x µl  H2O 10 µl total volume 
  
2.2.4.12     Cloning of CPT-Iα promoter fragment 
Synthesis of the -210/+19 CPT-Iα promoter fragment was carried out by PCR (2.2.4.2) 
using pGL3+rat CPT-Iα prom Fragment 2 gifted by E. A. Park (Jansen, at al., 2000) as 
template. In order to generate artificial restriction sites for directed ligation to the target 
vector pGL3, the oligonucleotides (2.1.10.1) were constructed. The forward primer was 
designed to produce a Sac I site, whereas the reverse primer was modified by generating a 
BglII site. The amplificated CPT-Iα promoter fragment (pGL3 + rat CPT-IαProm Frag3) 
contains a genomic region of 229 bp. 
 
2.2.5 Biochemical  Methods 
 
2.2.5.1     Preparation of cell lysates 
Cells were grown and stimulated as described above (2.2.2). For harvesting, cells were 
washed twice with ice-cold PBS. Last traces of PBS were removed by a pipette tip attached 
to a vacuum pump. The cells were treated with Triton X-100 lysis-buffer  supplemented 
with protease inhibitors. To remove cellular debris, probes were centrifuged (13000 rpm, 2 II. Materials and Methods 
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min at 4°C). Finally the supernatants were stored at –80°C until use. Protein content was 
determined using the Roth Nanoquant Protein Assay. 
 
Preparation of cell lysates from skeletal muscle cells 
Skeletal muscle cell lysats were prepared from male Sprangue-Dawley rats. Hind leg 
muscle was removed and washed in ice-cold PBS buffer. Tissue was then placed 
immediately in 10 volumes of ice-cold Triton X-100 lysis buffer supplemented with protease 
inhibitor mix and homogenised by Hom. The homogenate was centrifuged at 10000 rpm for 
5 min to remove cellular debris. The supernatant was filtered through two layers of gauze 
stored at -80° C. 
 
2.2.5.2     Trichloroacetic acid (TCA) precipitation  
This method was used to concentrate proteins from a defined volume of cell culture 
supernatant  for Western blot analysis. Cell culture supernatants were cleared from cellular 
contaminations using a single centrifugation step (1000 rpm, 5 min at 4°C; Heraeus 
Megafuge 1.0, rotor 7570F). Then, 400 µl of 20 % trichloroacetic acid (TCA) were added to 
1 ml of conditioned cell culture supernatant, mixed and incubated for 30 min on ice. TCA-
precipitated proteins were concentrated by centrifugation (13000 rpm, 30 min, 4°C) and the 
protein pellets were lysed in 50 µl 2 x Laemmli-buffer. For sPLA2-IIA detection, Laemmli 
buffer without ß-Mt-OH or DTT was used. After neutralization with 1-5 µl of 1 M Tris/HCl, 
pH 9.5, the samples were ready to use for gel electrophoresis in  Western blot analysis.  
 
2.2.5.3   Acetone  precipitation   
This method was necessary to concentrate protein from mesangial cells lysates with low 
amount of protein. 
Lysates of the required protein amount (100-200 µl) were mixed with a threefold volume of 
ice-cold acetone and incubated overnight at 20°C. Samples with precipitated protein were 
then centrifuged (13000 rpm, 30 min, 4°C) and pellets were lysed in 40 µl of  2 x Laemmli-
buffer. 
 
2.2.5.4    Preparation of membrane fraction 
Because of location of CPT-Iα in the mitochondrial outer membrane, this method was 
preferable to accumulate CPT-Iα protein, to diminish high background and achieve much 
greater sensitivity in Western blot. However, ß-tubulin from mesangial cells and also actin 
from liver cells were not detectable in this protein preparation for protein loading control.  
Lysates of protein produced as described in 2.2.4.1 were the source for membrane 
fractions including mitochondria, and these were pelleted by centrifugation at 40000 rpm for II. Materials and Methods 
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1 hr (4°C) at a concentration of 40-100 µg protein from liver cells and 100-200 µg protein 
from mesangial cells. The membrane pellet was finally resuspended in 20-50 µl of 2 x 
Laemmli-buffer. Protein of the cytosolic fraction was precipitated with acetone or TCA as 
described above and used for negative control. 
 
2.2.5.5       Determination of protein concentration 
The amount of protein in cellular lysates was determined using the Roth Nanoquant Protein 
Assay (Bradford method; Bradford, 1976). 20 µl of the samples (1:2 - 1:100 prediluted in 
Triton X-100 lysis-buffer) were pipetted in duplicate into appropriate wells of a 96-well 
ELISA plate. 20 µl of different BSA concentrations (10, 25, 50, 75, 100 and 150 µg/ml) were 
used in duplicate as standards. 180 µl of Roti Nanoquant (Roth, 1:4.5 diluted in distilled 
H2O ) were added to each well. After 10 min of incubation at RT, the optical density was 
measured at 595 nm and reference wavelength 450 nm using a microplate reader (Bio 
Rad). The absorption values were calculated using the Microplate Manager 4.0 software 
(Bio Rad). 
 
2.2.5.6    Western blot analysis 
The Western blot technique represents a sensitive method to detect specific polypeptides 
within a complex mixture of proteins. Proteins are separated electrophoretically and 
transferred to a polyvinylidene fluoride (PVDF) membrane, which is subsequently 
incubated with antibodies specific for the protein of interest. Finally, the bound antibody is 
recognised by a second anti-immunoglobulin which is coupled to horseraddish peroxidase 
or alkaline phosphatase. The detection limit of this method ranges between 1 and 5 ng of 
an average-sized protein using the ECL-Detection Kit  by Amersham Pharmacia (Freiburg). 
 
SDS gel electrophoresis 
Electrophoretic separation of proteins was carried out in the discontinuous buffer system 
for SDS polyacrylamide gels as originally described by Laemmli [1970]. For detection of 
intracellular proteins, 100 µg of total protein from mesangial cell lysates and 40 µg from 
liver cell lysates were dissolved in 1 x Laemmli buffer (2.1.2.1). For detection of TCA-
precipitated proteins in the cell culture supernatants, 1 ml of the supernatants was used. 
For loading of the protein samples on the gel, they  were denatured by heating for 5 min at 
95°C or for 30 min at 40°C in the presence of SDS. Mercaptoethanol (2-ME) or DTT was 
added during denaturation to reduce disulfide bonds. Importantly, for immunodetection with 
the monoclonal anti rat-sPLA2-IIA antibody, the protein samples were treated with 2 x 
Laemmli buffer without any reducing reagents. A typical run was performed in 1 x PAGE II. Materials and Methods 
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running buffer (2.1.2.1) at  a constant current of 20 mA/cm
2
, until the bromphenol blue (dye 
indicator) reached the bottom of the resolving gel.  
The separating gel and stacking gel solutions were prepared as follows: 
Resolving gel:                                              Component volumes (ml) for 2 gels: 
                                                                        10 % (60-120 kDa)    15 % (< 60 kDa) 
H2O                                                                24                               13.8 
Acrylamide mix (30%)                                    20.1                             36.15 
Tris/HCl (1.5 M, pH 8.8)                                 15                                15 
 
SDS (10 %)                                                     0.6                               0.6 
APS  (10 %)                                                    0.6                               0.6 
TEMED                                                           0.03                             0.03                                
 
Stacking gel :                                              Component volumes  
      (ml) for 2 gels : 
                                                               
H2O                                                               18.2 
Acrylamide mix (30%)                                   4 
Tris/HCl (1.5 M, pH 6.8)                                7.5 
 
SDS (10%)                                                    0.3 
Ammonium persulfate (10%)                        0.09  
TEMED                                                         0.03 
 
The desired percentage of acrylamide in the gel depends on the molecular size of the 
protein to be separated. For the 88 kDa CPT-Iα, 10 % and for 15 kDa rat-sPLA2-IIA, 15% 
running gels were used to achieve best separation of proteins. For the control of protein 
loading, immunodetection with 44 kDa α- actin or 52 kDa ß-tubulin was carried out. To 
remove any antibodies from the membrane, it was washed overnight in blocking-buffer at 
4°C. Stripping of membrane was not necessary, because all proteins of interest were of 
different molecular sizes and well separated in the gels. 
 
Coommassie-Brilliant-Blue staining after SDS-PAGE 
The location of a protein in a gel and protein loading can be determined by Coommassie-
Brilliant-Blue staining. Detection of the protein in a gel by Coommasie-Brilliant-Blue 
depends on nonspecific binding of the dye to the protein. The detection limit is 0.3-1 µg 
protein/ band.  
All steps were carried out in volumes of 10-20 ml of the following solutions at RT with slow 
agitation on a shaker. The polyacrylamide gel was stained with Coommassie-Brilliant-Blue II. Materials and Methods 
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solution for 2 hr, followed  by destaining solution to obtain blue protein bands on a clear 
background.   
 
Transfer to PVDF membrane 
After gel electrophoresis, proteins were transferred to a PVDF membrane by electroblotting 
(Hoefer SemiPhor, Amersham Pharmacia, Freiburg). Prior to use, the PVDF membrane 
was activated in isopropanol for 15 s and subsequently rinsed in deionized water for 
additional 2 min. Six pieces of Blotting Paper (Sigma) were soaked in transfer buffer and 
positioned on the anode side of the transfer apparatus. The PVDF membrane was placed 
directly on the stack of blotting paper. The SDS gel containing the separated proteins was 
taken off the glass plates, rinsed shortly in transfer buffer, and placed on the top of the 
PVDF membrane. Finally, the gel was covered with six additional, transfer buffer-soaked 
blotting paper. Air bubbles were squeezed out by a roller apparatus. The upper electrode 
(cathode) was positioned on the top of the stack and a current of 0.8 mA/cm
2 (nearly 60 mA 
per mini gel) was applied. Transfer of proteins was carried out at RT and terminated after 
90 min. After blotting, the membrane was checked by Ponceau S staining for correct 
electrophoretic transfer and equal loading. The successful protein transfer can also be 
controlled by staining the blotted SDS gel with Coomassie-Brilliant-Blue (2.5 mg/ml 
Coomassie-Brilliant-Blue G250, 45% Methanol, 45% H2O and 10% acetic acid). 
 
Immunodetection 
After blotting, the PVDF membrane was directly soaked in a TBST-buffered BSA solution 
(1%) for 1 h at RT (or overnight at 4°C) to block non-specific binding sites. The membrane 
was subsequently exposed to primary antibodies, specific for the protein of interest and 
incubated overnight at 4°C or at RT.  
 
Antibody  Dilution   Block buffer    
Anti-CPT-Iα  1:2000  TBST –2 % BSA  overnight at 4°C 
Anti-rat-sPLA2-IIA  1:100  PBS-1 % milk 
powder 
overnight at 4°C 
ß-tubulin   1:1000  TBST-1 % BSA  1 h at RT 
Actin  1:1000  TBST- 1 % BSA  1 h at  RT 
 
 
The blot was washed four times for 10 min in 1x TBST. Specific binding of primary antibody 
was detected by incubation of the membrane with a secondary antibody coupled to 
horseraddish peroxidase diluted at 1:15.000-1:20.000 in 1x TBST for 1 h at RT. For II. Materials and Methods 
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detection of the corresponding bands, the enhanced chemiluminescence (ECL) detection 
kit (Amersham Pharmacia) was used according to the manufacturer’s instructions. The 
membrane was exposed to a special ECL film (Amersham Pharmacia) and developed 
using Hyperprocessor, Amersham Pharmacia. Developed films were scanned (GS 700 
Imaging Densitometer, Bio Rad) and analyzed using the Molecular Analyst software from 
Bio Rad. 
 
                                                                                                                              III. Results 
 
     42
III 
                               Results 
 
 3.1    Characterisation  of  CPT-Iα antibody  
 
The liver isoform of CPT-Iα, with a molecular size of 88 kDa, is expressed in all 
cells except skeletal muscle cells and white adipocytes (Cook et al., 2001). 
Therefore, in this part of the thesis, the ability of anti-CPT-Iα antibodies to detect 
this isoenzyme in protein lysates of liver and mesangial cells in comparison to 
skeletal muscle cells was tested by Western blot analysis. 
 
Protein lysates were prepared from the primary rat hepatocytes and mesangial cells 
after incubation in DMEM medium for 24 hr. For negative control, the tissue lysate 
from rat hind leg was prepared as described in Methods (2.2.5.1). Primary 
hepatocytes and skeletal muscle tissue were isolated from male Sprague-Dawley 
rats that had been starved for 24 hr (2.2.2.2). Cell lysates from primary hepatocytes 
containing 40 µg protein and from mesangial and skeletal muscle cells containing 
100 µg protein were used for loading of SDS-PAGE (10 %). Subsequently, protein 
was transferred to PVDF membrane  and  Western blot analysis was performed as 
described in 2.2.5.6. As seen in Fig. 3.1 (A), CPT-Iα (88 kDa) was detectable on 
the Western blot by the antibody generated against this CPT isoenzyme in primary 
hepatocytes and mesangial cells. However, the required protein amount to detect 
CPT-Iα in mesangial cells was higher (100 µg) than that needed from liver cells (40 
µg). This was expected as the liver is a metabolically more active organ than the 
kidney. 
Also as expected, CPT-Iα was not detectable on the blot with protein samples of 
the skeletal muscle cells, as no bands corresponding to the size of 88 kDa were 
detectable. 
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Since CPT-Iα is integrated into the mitochondrial outer membrane (Fraser et al., 
1997), cytosolic and membrane fractions were prepared to increase the specificity 
and sensitivity of CPT-Iα detection.  
Cytosolic and membrane fractions from cell lysates containing 100 µg protein from  
hepatocytes and 50 µg from mesangial cells were prepared as described in 2.2.5.4  
and separated by SDS-PAGE (10 %) for Western blot analysis (Fig. 3.1  B)  
 
 
Figure 3.1  Characterisation of anti- CPT-Iα antibodies.  
(A)  Mesangial cell (MC) lysates were prepared from rat mesangial cell cultures after 
incubation in DMEM medium for 24 hr. Liver (LC) and skeletal muscle cell (SMC) lysates were 
prepared from isolated primary hepatocytes (2.2.2.2) and skeletal muscle tissue from male 
Sprague-Dawley rats starved for 24 hr. Thereafter, the cell lysates containing 40 µg protein 
from hepatocytes, and 100 µg from mesangial and skeletal muscle cells were taken for SDS-
PAGE (10 %) and subsequent Western blot analysis as described under 2.2.5.6. 
Cell lysates containing 50 µg protein from hepatocytes and 100 µg protein from mesangial 
cells were taken for preparation of membrane (B) and cytosolic fractions (C) as described 
under 2.2.5.4 and used for Western blot analysis.  
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As shown in Fig. 3.1 (B),  the antibody was able to detect CPT-Iα  only  in the 
membrane fraction, whereas a band of 88 kDa size was not detectable in the blot of 
the cytosolic fraction (Fig. 3.1 C). This was in agreement with the known localisation 
of this protein in the mitochondrial membrane. Moreover, due to the separation of 
membrane protein  from cytosolic protein, the clearance of unspecific bands on the 
blot detected by the anti-CPT-Iα antibody was markedly improved. Due to the time 
consuming isolation of membrane fraction, further Western blot  analyses were 
performed mostly with total lysates. Despite improved detection of CPT-Iα in blots 
with membrane fraction, the blots with total protein lysates were more suitable for 
protein loading control with anti-actin or -ß-tubulin antibodies. However, the 
preparation of membrane fraction was useful for cells lysates containing small 
amounts of protein. 
 
3.2    Stability of carnitine palmitoyltransferase-Iα  
protein  
 
One important aim of this thesis was to study the regulation of CPT-Iα protein 
expression under proinflammatory conditions. Thus, it was important to know, how 
fast the turn-over of this protein is, due to de novo-protein biosynthesis, during the 
time course of the experiments. In order to investigate the stability of CPT-Iα 
protein in mesangial cells and primary hepatocytes, cells were treated with the 
known protein synthesis inhibitor cycloheximide, and the CPT-Iα protein level was 
monitored by Western blot analysis. The cells were maintained in DMEM medium 
and then mesangial cells were treated with 10 µM cycloheximide for time period 
ranging from 2 to 24 hr. For primary hepatocytes 100 µM cycloheximide was used 
for a period from 2 to 8 hr, because at later time points cycloheximide was toxic to 
the cells. 
                                                                                                                              III. Results 
 
     45
 
 
 
Fig 3. 2   The time course of protein expression of CPT-Iα in rat mesangial cells  
(A) and primary hepatocytes  (B)  in the absence or presence of 
cycloheximide.  
(A) Rat  mesangial cells were treated with 10 µM and (B) rat primary hepatocytes with 100 
µM cycloheximide for the indicated time periods. Cell lysates containing 100 µg of protein 
from mesangial cells and 30 µg protein from hepatocytes were subjected to SDS-PAGE  
(10 %). Western blot analysis was performed using the CPT-Iα antibody at a dilution of 
1:2000 and subsequently with an anti-actin antibody for protein loading control from 
mesangial cell lysates or by Coommassie blue staining of the gel from hepatocytes protein 
lysates. 
 
CPT-Iα protein from mesangial cells and hepatocytes remained unchanged over 
the evaluated time period of 24 and 8 hr, respectively indicating that this protein, 
which is essential for basic metabolic functions, is very stable in both cell types at 
least during the time course of this study. This may indicate that even small 
increases in CPT-Iα protein amounts will have a significant effect on cellular lipid 
homeostasis. The purpose of the following studies was to search for conditions,                                                                                                                              III. Results 
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which would initiate an increase in CPT-Iα expression, and to investigate the 
regulatory mechanisms. 
 
3.3     Regulation of the expression of CPT-Iα by nitric 
oxide (NO) in rat mesangial cells and  
primary hepatocytes   
 
Nitric oxide (NO) has been identified as an universal intercellular messenger 
molecule regulating a variety of diverse cellular functions in many tissues. High 
amounts of NO produced by the inducible isoform of nitric oxide synthase (iNOS) 
can have beneficial microbicidal, antiviral, antiparasital, and antitumoral activity   
(Bogdan, 2001; MacMicking et al., 1997). In contrast, excessive and uncontrolled 
production of NO may have damaging consequences and seems to be involved in 
the pathophysiology of several human diseases and in particular, of acute and 
chronic inflammation (Pfeilschifter et al., 1995). Most tissue-derived cells are 
sensitive to the induction of iNOS when challenged with the proinflammatory 
cytokines, TNFα or IL-Iß. In particular in rat mesangial cells, IL-Iß is a strong 
stimulus for iNOS transcription (Pfeilschifter et al., 1990; Beck  et al., 1998).  
In a previous study (Gans 2003), it was shown that the NO donor DETA-NO 
induced CPT-Iα mRNA and protein expression in rat mesangial cells. Also,   
cytokines, like IL-Iß cause the production of NO by induction of iNOS in mesangial 
cells at the transcriptional level. In the present study, it was determined whether 
DETA-NO-induced CPT-Iα gene expression also occured at the transcriptional 
level. Moreover, the possible role of  NO/cGMP pathway in the induction of CPT-Iα 
mRNA and protein expression in rat mesangial cells was elucidated.   
 
Results: 
 
3.3.1  Effect of nitric oxide on CPT-Iα promoter activity in rat 
 mesangial cells 
It has been previously demonstrated, that high levels of nitric oxide released from 
the NO-donors (SNAP or SNP) caused an increased CPT-Iα activation (Garcia-
Villafranca et al., 2002). Furthermore, it was shown  more recently (Gans 2003) that 
DETA-NO upregulates CPT-Iα protein and mRNA expression. These studies were                                                                                                                               III. Results 
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continued, and the effect of DETA-NO on the CPT-Iα promoter activity in mesangial 
cells was performed to characterise the regulation of transcription.  
Mesangial cells were transfected with plasmids containing the CPT-Iα promoter in 
length of -4495/+19 linked to the luciferase reporter gene as described in 2.2.2. 
Subsequently, cells were stimulated for 24 hr with 200 µM DETA-NO, 2 nM IL-Iß or 
80 µM. These concentrations were shown to maximally stimulate CPT-Iα protein 
and mRNA expression at that time point (Gans 2003). Moreover, a previous study 
by Kunz et al. (1994) demonstrated that stimulation of mesangial cells for 24 hr with 
IL-1ß leads to increased  levels of iNOS mRNA and nitrite formation. Thus, it was 
presumed that, similar to the NO donor, IL-1ß-induced NO formation may trigger 
CPT-Iα promoter activity.  
 
 
 
Figure  3.3    Effect of the DETA-NO and IL-1β in comparison to palmitate on  
  C P T - I α promoter activity. 
 Mesangial cells grown in six-well plates were transfected for 16 hr with 400 ng of 
the -4495/+19 promoter DNA construct  plus 40 ng Renilla DNA (pRL-TK). After 24 h 
incubation with DETA-NO, 2 nM IL-1ß, or 80 µl palmitate, dual luciferase assays 
were performed as described in the Materials and Methods section (2.2.2.5). Values 
for luciferase were related to values for Renilla. */** Significant differences compared 
to vehicle as control (*  P< 0.1; ** P< 0.05).  
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  As shown in Fig. 3.3, DETA-NO and IL-1ß as well as palmitate stimulated a 
potentiation of CPT-Iα promoter activity by about twofold. In parallel, IL-1ß 
stimulated a significant increase in NO formation, measured as nitrite (40-fold) in 
comparison to control (date not shown).  
 
3.3.2 Involvement of nitric oxide/cGMP signaling pathway  on  
CPT-Iα expression in rat mesangial cells 
The aim of the next study was to investigate the role of cGMP as a downstream 
second messenger of NO for the CPT-Iα protein and mRNA expression. It is well 
known that IL-1ß-induced NO generation activates the soluble guanylate cyclase 
(sGC) in rat mesangial cells (Pfeilschifter et al., 1990). Therefore, in the next 
experiments cells were treated with ODQ, an inhibitor of sGC, or the sGC activator 
YC-1. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                              III. Results 
 
     49
 
 
 
 
 
Figure 3.4     Effect of sGC activator YC-1 on CPT-Iα protein expression and the 
sGC inhibitor ODQ on DETA-NO-induced CPT-Iα protein expression.  
Mesangial cells were treated for 24 hr with 100 and 200 µM DETA-NO in absence and   
presence of 200 µM ODQ (A) Mesangial cells were stimulated with 200 µM DETA-NO in 
absence and  presence of 200 µM ODQ or (B) with YC-1 at concentrations of 10 and 30. 
Thereafter, cells were lysed and 100 µg protein of cell lysate was taken for  SDS-PAGE (10%) 
and subsequent Western blot analysis with an antibody against CPT-Iα was performed. 
Protein loading was controlled by Coommassie-Brilliant-Blue staining. 
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Figure  3.5   Effect of the sGC inhibitor ODQ on DETA-NO-induced CPT-Iα mRNA 
expression.  
Mesangial cells were treated for 24 hr with 100 and 200 µM DETA-NO in the absence or  
presence of 200 µM ODQ. Total RNA was isolated and subjected to semiquantitative RT-PCR 
using specific  primers for CPT-Iα and GAPDH as described under 2.2.4. 
 
Treatment of mesangial cells with 100 and 200 µM DETA-NO for 24 hr resulted in a 
dose-dependent increase in CPT-Iα protein, which corresponds to the enhanced 
mRNA and promoter activity stimulated by this NO donor. 
Incubation of the cells with the sGC inhibitor ODQ (200 µM) resulted in a marked 
decrease of CPT-Iα protein and mRNA back to control levels or even below (Fig. 
3.4 A and 3.5). This suggests that the NO/cGMP pathway is crucial for a NO-
mediated increase in CPT-Iα expression. An amplification of CPT-Iα protein 
expression was also evident when mesangial cells were stimulated with YC-1 as an 
NO-independent activator of sGC (Fig. 3.4 B). However, this stimulation was not 
dose-dependent, because 10 µM YC-1 caused a higher CPT-Iα protein expression 
(2.2-fold) than 30 µM YC-1. This could be due to toxic effects of YC-1 at 
concentration of 30 µM. In the some experiments, ODQ alone stimulated a weak 
increase in CPT-Iα expression. This suggests that a basal cGMP generation might 
be involved in the maintenance of constant CPT-Iα levels.  
 
3.3.3  Effect of nitric oxide on CPT-Iα expression in primary rat 
hepatocytes 
It was further investigated whether DETA-NO has an effect on CPT-Iα expression 
in primary rat hepatocytes. Therefore, hepatocytes were stimulated for 24 hr with 
different concentration of DETA-NO. Protein and mRNA levels of CPT-Iα were 
analysed by Western blot (Fig. 3.6 A) and RT-PCR (Fig. 3.6 B), respectively. The                                                                                                                              III. Results 
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secretion of rat-sPLA2-IIA in supernatant after incubation was also analysed in 
Western blot for positive control of DETA-NO action and to check the 
responsiveness of hepatocytes to this NO donor (Fig. 3.6 C). 
 
 
Figure  3. 6    Effect of DETA-NO on CPT- Iα protein (A) and mRNA (B) expression in  
primary rat hepatocytes.  
(A) Primary hepatocytes were treated for 24 hr with DETA-NO at the indicated concentrations. 
Cell lysates containing 30 µg of protein were taken for isolation of protein from the membrane 
fraction as described in chapter 2.2.5.4 and subjected to SDS-PAGE (10% ). Subsequently, 
protein was transferred for Western blot analysis with the anti-CPT-Iα antibody,and protein 
loading was controlled by Coommassie-Brilliant-Blue staining. 
(B) Total RNA  was isolated from hepatocytes after treatment for 24 hr  with DETA-NO at the 
indicated concentration and subjected to RT-PCR using primers  for CPT-Iα and GAPDH.  
(C) Supernatants were taken for protein precipitation with TCA (2.2.5.2) and subjected to 
SDS-PAGE (15 %) and Western blot using anti-rat sPLA2-IIA antibody as described in 
Methods 2.2.6.  
 
As shown in the Fig 3.6, A and B, CPT-Iα protein and mRNA expression was not 
affected by DETA-NO treatment in hepatocytes in contrast to mesangial cells. On                                                                                                                              III. Results 
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the other hand, DETA-NO stimulation led to a clear induction of rat sPLA2-IIA in 
dose-dependent manner (Fig. 3.6, C). These data indicate that rat hepatocytes did 
response to treatment with DETA-NO to produce an increase in rat -sPLA2-IIA 
secretion, whereas CPT-Iα mRNA and protein expression was not altered. 
To investigate a putative role of endogenously produced NO, hepatocytes were   
stimulated with different cytokines for different time points and at different 
concentrations. Also, under these conditions, neither a change in CPT-Iα 
expression nor in iNOS expression and nitrite formation were detectable by 
Western blot analysis, RT-PCR and Griess assay (data not shown).   
  
3.4     Regulation of the expression of CPT-Iα 
          under hypoxic condition   
 
Hypoxia induces transcriptional regulation of a wide variety of genes encoding 
proteins necessary for cellular and physiological adaptation, including alterations  in 
metabolic events and energy consumption. In this respect, HIF-Iα is an important 
regulatory factor for this adaptation during hypoxia. It has been shown earlier that 
mesangial cells and hepatocytes in culture respond to hypoxia with changes in 
proliferation, matrix production and secretion of signalling molecules (Sahai et al., 
1997; Yuan et. al., 2000; Göpfert et al., 1996).  
However, the alterations of CPT-Iα in kidney and liver under hypoxia are poorly 
understood, and the observations in several studies are rather controversial.   
Moreover, nothing is known about the mechanisms of hypoxia-mediated effects on 
CPT-Iα in mesangial cells and hepatocytes.         
In the present study 3 series of experiments were performed. Series 1 was to 
investigate the regulation of the CPT-Iα protein and mRNA expression under 
hypoxic conditions in rat mesangial cells. Series 2 was performed to examine 
hypoxic effects on the CPT-Iα expression in rat hepatocytes and to compare this 
with mesangial cells in order to delineate tissue specific differences of regulation. 
Series 3 was performed to investigate whether hypoxia regulates mHMG-CoA 
synthase, another important enzyme in lypolysis.   
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Results: 
  3.4.1   Regulation of CPT-Iα  expression 
           under hypoxic conditions in mesangial cells 
First, the dose dependence of the hypoxia mimicing agent, CoCl2, on CPT-Iα 
protein expression was investigated by Western blot experiments. Mesangial cells 
were exposed to medium containing 100 µM or 200 µM CoCl2 for 16 and 24 hr (Fig. 
3.7)  and  cell  lysates containing 200 µg protein were taken for isolation of the 
membrane protein fraction.  
 
 
 
Figure 3.7  Western Blot analysis of CPT-Iα protein expression in mesangial cells 
treated with CoCL2. 
Mesangial cells were treated with 100 µM or 200 µM CoCL2 for 16 and 24 hr. Subsequently, 
cells were lysed and 200 µg protein of cell lysates was used for membrane isolation as 
described in 2.2.5.4. The pellet of the membrane fraction was subjected  to  the SDS - PAGE 
(10 %) and subsequently, Western blot analysis was performed with an anti-CPT-Iα antibody. 
Coommassie-Brilliant-Blue staining of the gel was performed for protein loading control.   
 
The data in Fig. 3.7 show that CoCl2 stimulated an about 2- to 3-fold increase in 
CPT-Iα protein in mesangial cells after 16 hr, however, this was not dose-
dependent and was not further increased during an incubation up to 24 hr. 
The next experiments were performed to examine the effect of CoCl2 on CPT-Iα 
mRNA expression, with respect to time and concentration of treatment. The 
mesangial cells were stimulated with 50, 150, 200, 400 mM CoCl2 for 24 hr                                                                                                                               III. Results 
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(Fig. 3.8 A) and with 100 µM CoCL2 for 2, 4 and 48 hr and changes in CPT-Iα 
mRNA expression were investigated by semiquantitative RT-PCR (Fig 3.8 B).  
 
     A  
 
 
 
Figure 3. 8    Effect of CoCl2 on CPT-Iα mRNA expression in rat mesangial cells.   
Mesangial cells were treated for 24 hr with CoCl2 at the indicated concentrations (A) and with 
100 µM CoCl2 for 2, 4 and 48 hr (B). Total RNA was isolated and CPT-Iα mRNA expression 
was analysed by performing semiquantitative RT-PCR as described under 2.2.4. 
 
As shown in Fig. 3.8 A and B, CPT-Iα mRNA levels were induced following CoCl2 
stimulation at the concentration range of 100 µM -200 µM. However, as shown in 
Fig. 3.7, the dose-dependency of CPT-Iα mRNA expression is not reflected by a 
dose-dependent increase in protein levels for yet unknown reasons. 
Incubation of mesangial cells with 400 µM CoCl2 did not induce a further increase in 
CPT-Iα expression, as this concentration was toxic to the cells. Moreover, it was 
observed that 48 hr of treatment with 100 µM CoCl2 caused some downregulation 
of constitutive mRNA expression, presumably due to apoptosis (Kakinuma et al., 
2001).  
The aim of the next study was to determine, whether an incubation of mesangial 
cells in an hypoxic cell culture environment, generated by the infusion of a gas 
mixture containing 3% O2 into the incubator, affects CPT-Iα mRNA and protein                                                                                                                                III. Results 
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expression. The effect of this hypoxic model was examined in comparison with 
CoCl2 and desferrioxamine (DFO) treatment.  
 
 
 
 
 
Figure 3. 9   Effect of hypoxia (3%), CoCl2 and DFO on CPT-Iα protein and mRNA  
expression in rat mesangial cells.  
Mesangial cells were incubated for 24 hr under hypoxic condition (3%) and  with 100 µM 
CoCl2 or 75 µM DFO under normoxic condition. Subsequently protein and total RNA was 
isolated for Western blot (A) and RT-PCR analysis (B). Membrane fractions isolated from 
lysats containing 100 µg protein (2.2.5.4) were taken for SDS-PAGE (10 % acrlyamid) and 
subsequently Western blot with anti-CPT-Iα antiserum. Commassie-Brilliant-Blue staining of 
the gel were used for protein loading control.  
 
The data in Fig. 3. 9 show that mesangial cells incubated for 24 hr during hypoxia 
(3% O2) or with CoCl2 (100 µM) and DFO (75 µM), during normoxia demonstrated 
an increase in CPT-Iα protein and mRNA expression.  
 
3.4.2   Regulation of the expression of CPT-Iα  
           under hypoxic conditions in primary rat hepatocytes   
First, the CoCl2 hypoxia model was used to characterise CPT-Iα mRNA and protein 
expression in rat primary hepatocytes. Western blot and RT-PCR analyses were 
performed with the membrane fraction of the protein and total RNA isolated from 
hepatocytes incubated with CoCl2 at a concentration range between 100 and 400 
µM.  
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Figure 3. 10  Effect of CoCl2 on CPT-Iα on protein (A) and mRNA (B) expression in 
rat primary hepatocytes.   
Primary rat hepatocytes were stimulated for 24 hr for protein analysis and 16 hr for mRNA 
expression analysis with either vehicle (control) or the indicated concentrations of CoCl2 
under normoxic condition.  
(A) Cell lysates containing 30 µg of protein were taken for isolation of the membrane fraction 
as described in chapter 2.2.5.4 and subjected to SDS-PAGE (10%). Subsequently, Western 
blot analysis was performed.  (B) Total RNA was isolated from the hepatocytes and subjected 
to semiquantitative RT-PCR analysis.  
 
As it is shown in Fig. 3.10 A, incubation of hepatocytes with 100 µM and 200 µM 
CoCl2  increased CPT-Iα protein expression in a dose-dependent manner. After 
stimulation with higher concentration of CoCl2 (300 µM and 400 µM) CPT-Iα protein 
levels fell under control levels, due to its toxic effect. An exposure of rat 
hepatocytes to 100 µM CoCl2 did not cause detectable changes in CPT-Iα mRNA 
levels. Incubation with 200 µM and 300 µM CoCl2 even decreased CPT-Iα mRNA 
levels, and stimulation with 400 µM CoCl2 presumably caused degradation of  RNA 
due to  toxicity,  which was estimated  from the agarose gel electrophoresis of total 
RNA (2.2.4.7). Thus, it was not possible to analyse the effect of this concentration 
on CPT-Iα mRNA expression by RT-PCR.  
Interestingly, the regulation of CPT-Iα by CoCl2 in hepatocytes is in marked contrast 
to its effects in mesangial cells (see data in Fig. 3.7 and 3.8).                                                                                                                               III. Results 
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In the next study, the effect of hypoxia (1% O2) in comparison to CoCl2 and DFO on 
CPT-Iα mRNA expression was  examined. Primary hepatocytes were incubated 
under hypoxic conditions of only 1% oxygen, or with CoCl2 (100 µM) or DFO  
(75 µM) under normoxia for 2, 4 and 24 hr (Fig. 3.11).  
 
 
 
 
 
Figure 3.11   Effect of hypoxia (1%), CoCl2 and DFO on CPT-Iα mRNA expression in 
rat hepatocytes.   
Primary rat hepatocytes were incubated for 2, 4 and 24 hr under hypoxic condition 
1% O2) or with 100 µM CoCl2 or 75 µM DFO under normoxic condition. 
Subsequently, total RNA was isolated and semiquantitative RT-PCR analysis was 
performed.  
 
As shown in the Fig. 3.11, the CPT-Iα mRNA level began to decrease between 2 
and 4 hr of  hypoxic exposure and remained below control levels up to 24 hr. In 
contrast, after treatment of the hepatocytes with 100 µM CoCl2,  CPT-Iα mRNA 
levels remained unchanged. A slight induction of CPT-Iα mRNA was observed after 
24 hr of treatment with 75 µM DFO. These results demonstrate marked differences 
between the hypoxic culture environment generated by 1 % O2 and by the hypoxia-
mimicking compounds CoCl2  and DFO, which may be the result of affecting 
different regulatory pathways. Moreover, the oxidative fatty acid metabolism might 
be drastically reduced due to the lack of oxygen (1 % instead of 3 % oxygen in the 
cell culture environment).   
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3.5    Regulation of the mHMG-CoA synthase mRNA 
under hypoxic conditions in rat mesangial cells 
and primary hepatocytes 
 
Results shown above indicated  that different models of hypoxia cause changes in 
CPT-Iα protein and mRNA expression in rat mesangial and primary hepatocytes. 
The next experiments were performed to investigate whether expose of rat 
mesangial and primary hepatocytes to hypoxic conditions cause a similar alteration 
in expression of mHMG-CoA mRNA synthase, another enzyme important for FA 
oxidation rate. 
 
 
 
 
Fig. 3.12   Effect of hypoxia (3 %), CoCl2 and DFO on mHMG-CoA synthase mRNA 
expression in rat mesangial cells.   
Rat mesangial cells were incubated for 24 hr under hypoxic condition (3% O2), or with 100 µM 
CoCl2, or 75 µM DFO under normoxic condition. Subsequently, total RNA was isolated and  
subjected to semiquantitative RT-PCR analysis with specific primers for mHMG-CoA synthase 
as described under 2.2.4.2. 
 
As is shown in the Fig. 3.12, mHMG-CoA synthase mRNA in rat mesangial cells 
was downregulated in response to hypoxia (3% O2), CoCl2 (100 µM), or DFO (75 
µM) after 24 hr.   
Next, mHMG-CoA synthase mRNA expression was examined in rat primary 
hepatocytes. For this propose, the cells were exposed to more pronounced hypoxia 
(1 % O2), or treated with CoCl2 (100 µM), or DFO (75 µM) under normoxic condition 
for 2, 4, or 24 hours.                                                                                                                                  III. Results 
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Fig. 3.13   Effect of hypoxia (1%), CoCl2 and DFO on mHMG-CoA synthase mRNA 
expression in rat hepatocytes.  
Primary rat hepatocytes were incubated for 2, 4 and 24 hr under hypoxic condition 
(1% O2) and  with 100 µM CoCl2 or with 75 µM DFO under normoxic condition. 
Subsequently total RNA was isolated and subjected to RT-PCR analysis as 
described  under 2.2.4.2. 
 
Exposure of rat hepatocytes to a hypoxic environment of a gas mixture containing 
1% O2 or to 100 µM CoCl2, or 75 µM DFO resulted in a decrease of mHMG-CoA 
synthase mRNA reaching lowest levels after 24 hr (Fig. 3.13). These results 
indicate that all three models of hypoxia cause a downregulation of mHMG-CoA 
synthase mRNA expression. The reduction induced by 1 % O2 was obvious after 
only 4 hr, whereas CoCl2  and DFO displayed their reducing effects after 24 hr.  
 
3.6 Regulation of CPT-Iα expression by exogenous 
secreted phospholipase A2-IIA in rat mesangial and 
primary rat hepatocytes 
 
3.6.1  Effect of exogenously added human sPLA2-IIA  and TNFα  on 
the CPT-Iα protein expression in rat mesangial cells 
The elevated concentration of sPLA2s under inflammatory conditions causes an 
increased release of FFAs and further proinflammatory lipid metabolites from 
glycerophospholipids such as lysophospholipids and eicosanoids, (Kudo and 
Murakami, 2002). As previous studies reported that FFAs upregulate CPT-Iα 
expression in different cell types (Clarke et al., 2003; Assimacopoulos-Jeannet et                                                                                                                              III. Results 
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al., 1997), we have  hypothesised  a similar effect on CPT-Iα by  FFAs, which were 
released via exogenously added sPLA2s in mesangial  and liver cells. 
The dose dependence of exogenously added h-sPLA2-IIA on CPT-Iα protein 
expression was investigated by Western blot analysis using a polyclonal antibody 
against rat CPT-Iα. Mesangial cells were stimulated for 24 hr with medium 
containing human recombinant sPLA2-IIA (h-sPLA2-IIA) at concentration of 0.1 µM 
and 0.3 µM. These concentrations  were chosen, as previous studies demonstrated 
that thay produced  optimal stimulation of prostaglandin synthesis and rat-sPLA2-IIA 
secretion in these cells (Beck et al., 2003). Subsequently, mesangial cells were 
harvested and 100 µg of cell lysate was used for Western blot analysis.   
The treatment of mesangial cells with different concentrations of h-sPLA2-IIA 
  (0.1 µM and 0.3 µM) resulted in a dose-dependent increase in CPT-Iα protein 
levels as is shown in Fig. 3.14. Higher concentrations of this enzyme did not show a 
further increase in CPT-Iα  protein amount (data not shown). 
 
 
 
 
Fig. 3.14   Effect of h-sPLA2-IIA on CPT-Iα protein expression.  
Rat mesangial cells were cultured for 24 hr in DMEM medium containing 0.1 µM and 0.3  µM 
h-sPLA2-IIA. 100 µg protein from total cell lysates were first subjected to SDS-PAGE (10 % 
acrylamide gel) and transferred to PVDF membrane. Western blot analysis was performed 
with an antibody against CPT-Iα and subsequently for protein loading control, with an anti-ß-
tubulin antibody as described in 2.2.5.6.    
 
Exogenously added sPLA2s are known to amplify the cytokine-stimulated 
expression of sPLA2-IIA in rat mesangial cells. This enhanced expression occurs at 
the mRNA and protein level and finally results in an increased secretion of the rat 
sPLA2-IIA protein into the cell culture medium (Scholz-Pedretti et al., 2002; Beck 
 et al., 2003). Therefore, the aim of the next experiment was to determine whether 
the CPT-Iα expression is potentiated after costimulation of h-sPLA2-IIA with 
TNFα in comparison to treatment with h-sPLA2-IIA  alone.                                                                                                                               III. Results 
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Fig. 3.15  Effect of h-sPLA2-IIA and TNFα on CPT-Iα protein expression.  
Mesangial cells were stimulated for 24 hr with 0.1 µM h-sPLA2-IIA in the presence or absence 
of 0.5 nM TNFα.  30 µg protein from total cell lysates was taken for SDS -PAGE  
(10 %) Western blot analysis was performed with an anti-CPT-Iα antibody and subsequently 
with an anti-actin antibody for control of protein loading.    
 
As shown in Fig. 3.15, costimulation of h-sPLA2-IIA with TNFα elicits a 3.7-fold 
increase in CPT-Iα protein amount compared to an about 2-fold increase after 
treatment with h-sPLA2-IIA and TNFα as single agents.  
 
3.6.2   Effect of cycloheximide on h-sPLA2-IIA or TNFα 
induction of CPT-Iα protein expression in rat mesangial 
cells. 
To investigate whether de novo protein biosynthesis is involved in the increased 
expression of CPT-Iα by h-sPLA2-IIA and TNFα, mesangial cells were incubated for 
different time points with 0.5 nM TNFα and 0.1 µM h-sPLA2-IIA in presence or 
absence of the protein synthesis inhibitor cycloheximide (CHX). The cells were then 
lysed and CPT-Iα protein expression was analysed by Western blotting. 
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Fig.  3.  16      Effect of cycloheximid (CHX) on upregulation of CPT-Iα protein 
expression  after treatment  with h-sPLA2-IIA and TNFα.  
Mesangial cells were treated for 24 hr with h-sPLA2-IIA (0.1 µM) or TNFα (0.5 nM) in the 
absence or presence of 10 µM CHX, or with 10 µM CHX alone. The cells were lysed and 100 
µg protein of total cell lysates was taken for SDS -PAGE (10 %). Western blot analysis was 
performed with an anti-CPT-Iα antibody and subsequently with an anti-ß-tabulin antibody for 
control of protein loading.    
 
Western blot analysis showed an increase in CPT-Iα protein level 24 hr after 
incubation with h-sPLA2-IIA and TNFα (Fig. 3.16 ). In the presence of CHX, the 
increase in CPT-Iα protein expression was diminished indicating that the enhanced 
protein expression is indeed dependent on de novo protein biosynthesis. However, 
the reduction in CPT-Iα protein level did not reach the level of the control group. 
Furthermore, treatment with CHX alone in this experiment induced CPT-Iα protein 
expression. This effect could be explained by an inhibition of protein synthesis by 
CHX resulting in a reduced level of the enzymes which are responsible for CPT-Iα 
protein degradation. 
3.6.3   Regulation of CPT-Iα expression by exogenous secreted 
phospholipase A2-IIA and TNFα in rat primary hepatocytes 
It was further investigated as to whether the up-regulation of CPT-Iα  by exogenous 
sPLA2s as well as TNF-α occurs in rat primary hepatocytes. For this purpose, 
freshly isolated rat primary hepatocytes were stimulated for 24 hr with 0.1 µM  
h-sPLA2-IIA in the presence or absence of 0.5 nM TNFα. Thereafter, the cells were 
lysed, and CPT-Iα protein level was analysed by Western blotting.                                                                                                                              III. Results 
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Fig. 3. 17  Effect  of  h-sPLA2-IIA and TNFα on CPT-Iα (A) and endogenous rat-
sPLA2-IIA (B) protein expression.  
Hepatocytes were treated for 24 hr with h-sPLA2-IIA (0.1 µM) in the absence or presence of 
TNFα (0.5 nM). 
(A) 100 µg of hepatocytes- protein lysates were subjected to SDS-PAGE (10%) and 
transfected to PVDF membranes. Western blot analysis was performed with anti-CPT-Iα 
antiserum. Coomassie staining was used for protein loading control. 
(B) 1 ml cell culture supernatants were taken for r- sPLA2-IIA precipitation as described under 
2.2.5.2 and protein samples were subjected to SDS-PAGE (15% ) and transfected to PVDF 
membranes. Western blot analysis was performed with anti r-s PLA2-IIA antibodies as 
described under 2.2.5.6. 
 
 
 
                                                                                                                              III. Results 
 
     64
Fig. 3.17(A) shows that h-sPLA2-IIA and TNFα alone triggered an increase in  
CPT-Iα protein expression. In contrast to the observation in rat mesangial cells, the 
combination of h-sPLA2-IIA and TNFα did not result in a considerable potentiation 
of the stimulation CPT-Iα protein expression. 
From the same experiment, rat-sPLA2-hIIA protein secretion into the cell culture 
supernatants was analysed by Western blotting and used as a positive control. It 
was shown earlier that sPLA2-IIA is constitutively expressed in rat liver (Kudo and 
Murakami, 2002). Additionally, rat hepatocytes show increased plasma group II 
PLA2 activity, detectable under proinflammatoric conditions (Bertsch and Fischer, 
1999; Talvinen et al., 2001). As expected, TNFα triggered a significant increase in 
rat-sPLA2-IIA protein into the cell culture supernatants. Interestingly, in contrast to 
rat mesangial cells (Fig. 3.17. B), secreted rat-sPLA2-IIA protein was also 
detectable in supernatants from untreated hepatocytes, confirming the observation 
by Kudo (2002). Stimulation with human sPLA2-IIA alone caused a considerable 
increase in sPLA2-IIA secretion, which was not observed in rat mesangial cells. It is 
important to note at this point that the antibody used to detect rat sPLA2-IIA does 
not detect the human enzyme given exogenously and does not cross-react with 
other known sPLA2 enzymes which might be released from the hepatocytes and 
mesangial cells (Beck et al., 2003). 
 
3.6.4    Effect of exogenous sPLA2s (0.1µM) from different  
   species  on  CPT-Iα mRNA expression in mesangial cells 
It is known that in many cell types free long-chain-fatty acids rapidly upregulate 
CPT-Iα mRNA expression in a dose-dependent manner, which is accompanied by 
an increase in CPT-Iα activity  (Chatelain, et al., 1996; Louet, et al., 2001 [a; b]). 
Therefore, in addition the effects of exogenous sPLA2s and TNFα  as FFA-realising 
agents on the CPT-Iα mRNA level were investigated using semi-quantitative RT-
PCR analysis.  
Rat mesangial cells were treated for 24 hr with various sPLA2s from mammalian 
and venom origins (2.1.4.1) at a concentration of 100 nM in comparison with TNFα. 
These enzymes were previously shown to stimulate endogenous rat-sPLA2-IIA 
secretion via FFA and their metabolites in rat mesangial cells. The effect of a 
catalytically inactive mutant of porcine sPLA2-IB containing a single amino acid 
mutation at position 48 (H48Q) was also investigated. This mutant is able to bind to                                                                                                                              III. Results 
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the rat sPLA2 receptor and thereby activates expression and secretion of rat sPLA2-
IIA in medium culture by indirect mechanisms involving cytosolic phospholipase A2 
(cPLA2) (Beck et al., 2003).  
 
 
 
 
Fig. 3.18   Influence of exogenous added sPLA2s and TNFα on CPT-Iα mRNA  
expression in rat mesangial cells.  
Mesangial cells were treated for 24 hr with TNFα (0.5 nM) or with 0.1µM of human sPLA2-IIA 
(hIIA), porcine sPLA2-IB (IB), the catalytically inactive mutant sPLA2-IB -H48Q (H48Q), rat 
sPLA2-IIA (rat IIA), sPLA2 from N. mossambica mossambica (Naja), sPLA2-III from bee 
venom (Bee), and two snake venom sPLA2s from Oxyuranus scutellatus sc. (OS1, OS2).  
W, wild-type. 
Total RNA  was extracted from cell lysates, and RT-PCR was performed to detect CPT-Iα 
mRNA expression as described in 2.2.4.1.  
 
All phospholipases, as well as, TNFα were able to enhance the mRNA expression 
of CPT-Iα in mesangial cells (Fig. 3.18). Furthermore, different  experiments did not 
show much difference in regulation between enzymes studied. Interestingly, the 
catalytically inactive H48Q mutant of sPLA2-IB was able potentiate the expression 
of rat CPT-Iα mRNA, suggesting an involvement of the sPLA2 receptor.  
 
3.6.5 Dose-response of CPT-Iα mRNA expression by exogenously  
added human sPLA2-IIA and TNFα in mesangial cells  
In the following experiment, the mRNA expression of CPT-Iα was analysed with two 
different concentrations of h-sPLA2-IIA (0.1 µM and 1 µM) in the presence or 
absence of 0.5 nM TNFα  (Fig. 3.19 ).                                                                                                                                III. Results 
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Fig. 3. 19  Effect of h-sPLA2-IIA and TNFα on CPT-Iα mRNA expression.  
Mesangial cells were treated for 24 hr with h-sPLA2-IIA at the indicated concentrations in the 
presence or absence of  0.5 nM TNFα, or with TNFα alone. Total RNA was isolated and CPT- 
Iα mRNA expression was analysed by performing RT-PCR as described under 2.2.4.2. 
 
As shown in Fig. 3.19,  h-sPLA2-IIA altered CPT-Iα mRNA level in rat mesangial 
cells in a dose-dependent manner. Treatment with TNFα, as a single effector, also 
markedly increased the CPT-Iα mRNA. Moreover, TNFα produced an additive 
effect on h-sPLA2-IIA- induced accumulation of CPT-Iα mRNA. This potentiation 
corresponds to that observed for the CPT-Iα protein expression (see chapter 3.6.1). 
    
3.6.6   Effect of exogenous human sPLA2-IIA and TNFα on the 
  C P T - I α promoter activity 
To further investigate the molecular mechanisms involved in the regulation of CPT-
Iα gene expression by h-sPLA2-IIA and TNFα, transient transfections of plasmids 
containing the CPT-Iα promoter of different lengths ( -4495/+1240, -4495/+19  
or -210/+19) and linked to the luciferase reporter gene, were performed as 
described in  2.2.2.  
Mesangial cells transfected with the -4495/+1240 construct of the rat CPT-Iα 
promoter fused to a luciferase reporter gene (Park et al., 1998; Jansen M, et al., 
2000) responded to treatment with h-sPLA2-IIA (0.1 µM) and TNFα (0.5 nM) with a 
marked increase in luciferase activity (Fig. 3.20 A). However, the costimulation of 
sPLA2-hIIA with TNFα did not show a potentiating effect. Similar results were 
obtained from transfection of mesangial cells with the -4495/+19 construct 
 (Fig. 3.20 B). No effect was seen in mesangial cells transfected with the -210/+19 
construct (Data not shown).                                                                                                                              III. Results 
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 One possible mechanism, by which sPLA2s may act on CPT-Iα expression, is the 
action of released lipid metabolites such as free FAs and prostaglandins via 
peroxisome proliferator-activated receptors PPARs. As natural ligands of PPAR, 
fatty acids may activate CPT-Iα gene expression by recognition of the peroxisome  
proliferator responsive element (PPRE) exhibited  in the proximal CPT-Iα promoter 
(-2859/-2846). To characterise the functionality of PPRE on the CPT-Iα gene, 
mesangial cells were transfected with the -4495/+1240 promoter construct 
containing  PPRE and the first intron. Then, cells were stimulated with 50 µM of the 
PPAR-α activator Wy14.643 and 100 µM of palmitate. As shown in Fig. 3. 20 A, 
both Wy14.643 and palmitate stimulated CPT-Iα promoter activity. 
Interestingly, the CPT-Iα promoter activity in mesangial cells transfected with the 
 -4495/+19 promoter construct containing PPRE but without the first intron was also 
stimulated with WY14.643 and palmitate (Fig. 3. 20 B).  
 
A 
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Fig.  3.  20  Effects of the human sPLA2-IIA, TNFα as well as WY 14.643 and 
palmitate on the CPT Iα promoter activity (-4495/+1240 (A) or -4495/+19 
(B) constructs). 
Mesangial cells grown in six-well plates were transfected overnight with 400 ng of  
-4495/+1240 (A) or -4495/+19 (B) CPT-Iα promoter DNA linked to luciferase plus 40 ng 
Renilla-luciferase DNA (pRL-TK). After 24 h incubation with h-PLA2-IIA (100 µM) in the 
absence or presence of TNFα (0.5nM), TNFα (0.5nM) as single agent, WY14.643 (50 µM) 
and palmitate (100 µM), dual luciferase assays were performed as described in the Materials 
and Methods section 2.2.2. Values for luciferase were related to values for Renilla.  
 
TNFα and h-sPLA2-IIα alone significantly (~2-fold) stimulated luciferase activity, 
whereas the addition of both effectors did not result in a potentiation of luciferase 
activity. These results suggested that TNFα and h-sPLA2-IIA increase CPT-
Iα expression at the promoter level, which corresponds to the effects obtained at 
the protein and mRNA level. 
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  3.6.7  Human sPLA2- and TNFα-induced upregulation of  
 CPT-Iα protein expression may involve mitogen-activated 
 protein kinase (MAPK)-pathway in mesangial cells  
To further elucidate the signal transduction pathways by which sPLA2-IIA and TNFα 
increase CPT-Iα expression, the role of mitogen-activated kinase ERK-1/2 (MAPK) 
was tested. MAPKs are known to play an important role in activation of cPLA2 
through phosphorylation and targeted by specific low molecular mass inhibitors 
(English and Cobb, 2002). The cPLA2 inhibition may lead to diminished formation of 
lipid mediators and sPLA2-IIA in mesangial cells and may thus influence CPT-Iα 
expression. Mesangial cells were treated with 0.1 µM h-sPLA2-IIA and 0.5 nM 
TNFα in the absence or presence of 1 µM U0126, which is a selective inhibitor of 
the MAPK kinase MEK, or in the presence or absence of 10 µM PD98059, a 
selective inhibitor of ERK-1/-2 (Favata et al., 1998). These are typical inhibitory 
concentrations of both compounds. 
As seen in Fig. 3. 21 A and B, the inhibition of the MAPK pathway caused a 
decrease in h-sPLA2-IIA- and TNFα-induced CPT-Iα protein expression in 
mesangial cells. The 2.1-fold TNFα-induction of CPT-Iα protein expression was 
abolished to 1.7-fold with PD 98059 and to 1.5-fold with U0126, and 2.5-fold  
sPLA2-IIA-induction was abolished to 1.8-fold with PD 98059 or U0126. These 
results demonstrated that the reduction of TNFα-mediated CPT-Iα protein increase, 
by inhibition of the MAPK pathway, does not occur to the level in the control group. 
This suggests that the constitutively expressed basal CPT-Iα protein seems to be 
rather stable and is not under the control of the MAPK pathway in mesangial cells.  
Interestingly, both inhibitors alone caused an increase in CPT-Iα protein expression 
(U0126 weakly: 1.2-fold, and PD 98059 more pronounced: 1.8-fold).This could be a 
result of  the long-term inhibition of the MAPK pathway for 24 h, which may affect 
further critical steps in protein biosynthesis in general. 
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Fig. 3. 21    Effect of the MAPK inhibitors U0126 and PD98059 on h-sPLA2-IIA and 
TNFα - induced CPT-Iα protein expression. 
Mesangial cells were treated for 24 hr with h-sPLA2-IIA (0.1 µM) and TNFα (0.5 nM) in the 
absence or presence of 10 µM PD98059 (A). Mesangial cells were treated for 24 hr with 
sPLA2-hIIA (0.1 µM) and TNFα (0.5 nM) in absence and  presence of 10 µM PD98059 or 1                                                                                                                              III. Results 
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µM U0126 (B). 1 ml of the cell culture supernatants were taken for rat sPLA2-IIA protein 
detection by Western blot analysis as described under 2.2.5. (C). 
100 µg protein of the cell lysate were subjected to SDS-PAGE (10% PAGE), and Western 
blot analysis was performed with an antibody against CPT-Iα and subsequently with actin for 
protein loading control. Protein samples form supernatants were subjected to  SDS-PAGE (15 
%), and protein levels were detected with anti-rat- sPLA2-IIA antibody by Western blotting. 
 
Induction of the expression and secretion of sPLA2-IIA in mesangial cells by 
cytokines has been extensively reviewed (Schalkwijk, et al., 1991; Scholz, et al., 
1999; Scholz-Peretti, et al., 2002). In this study the MAPK inhibitory effect of U0126 
and PD98059 on TNFα-induced sPLA2-IIA enzyme secretion was monitored. The 
cell culture supernatants of mesangial cells treated with both inhibitors were 
analysed for sPLA2-IIA protein by Western blotting with an anti-rat sPLA2-IIA 
antibody as described in 2.2.4.2.  
As seen in Fig. 3. 21 C, rat sPLA2-IIA protein level was detectable in the cell culture 
supernatants of TNFα-stimulated mesangial cells, as described in the previous 
studies, and was used here as positive control. A coincubation of mesangial cells 
with TNFα and the inhibitors resulted in a decrease of secreted rat sPLA2-IIA 
protein level.  
In summary, these results suggest that extracellular sPLA2-IIA stimulates an 
enhanced expression of CPT-Iα, probably via endogenous lipid metabolites, which 
were either produced directly or generated via cPLA2, and that this involves MAPK 
activation. 
3.7   Regulation of mHMG-CoA synthase mRNA expression 
by exogenous sPLA2s and TNFα in rat mesangial 
cells 
 
Additionally to CPT-Iα, several authors suggest that mitochondrial 3-hydroxy 3-
methylglutaryl coenzyme A synthase (mHMG-CoA synthase), the enzyme that 
catalyses formation of HMG-CoA in mitochondria, is another important site for 
control of ketogenesis (Ayte et al., 1990). It has been shown that  fatty acids induce 
the transcription of the gene for mHMG-CoA synthase both in vivo and in vitro  
(Hegadt, 1999) and this induction is meditated by PPARα, which binds to PPRE 
located in the mHMG-CoA synthase promoter (Rodriguez et al., 1994). With                                                                                                                              III. Results 
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thibackground, we investigated the role of exogenously added sPLA2s as well as 
TNFα on mHMG-CoA synthase mRNA.     
 
Results: 
After stimulation of rat mesangial cells for 24 hr with TNFα or exogenous sPLA2s  
from different species (see 2.1.4.1) in absence or presence of TNFα, the mHMG-
CoA synthase mRNA expression was analysed  by RT-PCR as described in 2.2.3.   
sPLA2s stimulated a marked increase in mHMG-CoA synthase mRNA expression, 
only after costimulation of sPLA2s with TNFα (Fig. 3.22). Neither TNFα or the 
different sPLA2s alone had an inducing effect.  
   
 
 
Fig. 3. 22  Effect of h-sPLA2-IIA and TNFα on mHMG-CoAs mRNA expression.   
Mesangial cells were treated for 24 hr with 0.5 nM TNFα and h-sPLA2-IIA at the 
concentrations of 0.1 µM in the presence or absence of 0.5 nM TNFα. Total RNA was isolated 
and mHMG-CoA synthase  mRNA expression was analysed by performing RT-PCR as 
described under 2.2.4.2. 
 
While CPT-Iα mRNA expression was enhanced after stimulation with h-sPLA2-IIA 
or TNFα as single agents compared to control cells, the mHMG-CoA synthase 
mRNA level was not altered under these conditions. On the other hand, mHMG-
CoA synthase mRNA level was markedly increased by the costimulation of h-
sPLA2-IIA with TNFα.  These preliminary results suggest that under 
pathophysiological conditions, cytokines act in  concert with extracellular sPLA2s to 
induce mHMG-CoA synthase as an important enzyme for the metabolism of surplus 
free fatty acids to ketone bodies. 
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The analysis of HMG-CoA synthase protein is not possible because of the lack of 
specific antibodies for this enzyme. In future studies, the analysis of ketone bodies 
will be performed as a read out for an increased enzyme expression. 
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      IV 
Discussion 
___________________________________ 
    
4.1  Characterisation of CPT-Iα antibody  
 
Of the two isoforms of CPT-I (CPT-Iα and CPT-Iß), only isoform CPT-Iα is 
expressed in most tissues including liver and kidney. CPT-Iα is not detectable in 
skeletal muscle or brown adipocytes, whereas CPT-Iß is the predominant isoform in 
these tissues. This knowledge, together with the fact that this enzyme is located on 
the mitochondrial inner membrane, was used in the present study to characterise 
the specificity of the available anti-CPT-Iα antiserum. The antiserum (provided by 
Prof. Pfeilschifter) was raised in rabbit against an epitope of liver isoform CPT-Iα, 
which is not expressed on the CPT-Iß isoform. 
To confirm that the antiserum recognises CPT-Iα in rat mesangial cells and primary 
hepatocytes, Western blot analysis was performed on protein from cell lysates of 
these cells. As negative control, skeletal muscle cells were analysed. The specificity 
of the antiserum was proved by the following facts: 1) a major band of 88 kDa, 
which corresponds to the molecular mass of rat CPT-I (McGarry and Brown, 1997; 
Esser et al., 1993), was observed in the blots; 2) antibody raised against rat liver 
isoform CPT-Iα recognises this protein in rat primary hepatocytes and mesangial 
cells but not in skeletal muscle, where only CPT-Iß isoform is expressed. 
Furthermore, much less protein from hepatocytes was needed for optimal detection 
by Western blotting (40 µg) in comparison to mesangial cells, where 100 µg protein 
was required. This suggests that mesangial cells express lower levels of the CPT-
Iα than hepatocytes. These results are in accordance with the fact that the liver is 
the most important central metabolic site which provides a major source of energy 
from mitochondrial fatty acid oxidation and thus, much higher CPT-Iα protein level 
are required. Further evidence for the specificity of the CPT-Iα antiserum was a 
Western blot analysis of protein from the membrane fraction of the cell lysates. As    IV. Discussion 
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expected, the CPT-Iα was only detectable in the membrane fraction, which included 
mitochondrial membrane proteins.     
 
4.2   Stability of CPT-Iα protein 
 
There are few studies characterising the CPT-I mRNA or protein stability, this 
stability significantly influence the action of various agents on the protein level and 
subsequently on FA homeostasis in the cells. For instance, it was shown that the 
protein synthesis inhibitor cycloheximide (CHX) inhibits the effect of FAs on CPT-I 
mRNA while it has no effect on its  constitutive expression as it was analysed in the 
ß-cell line INS-1 after 6 hr incubation (Assimacopoulos-Jeannet et al., 1997). Thus, 
the CPT-I gene was characterised in INS-1 cells as an early-response gene whose 
induction is depended on the action of pre-existing factors and does not require de 
novo protein synthesis. Nothing is known about stability of CPT-Iα protein in rat 
mesangial cells and primary hepatocytes. In the present work, the incubation of 
mesangial cells for 2-24 hr and hepatocytes for 2-8 with CHX did not change CPT-
Iα expression levels indicating a slow turn-over and/or a long half-life of the protein. 
Moreover, de novo protein synthesis is required for the observed upregulation after 
stimulation of these cells under inflammatory conditions (see Chapter 4.5) as the 
enhanced CPT-Iα level through sPLA2-IIA was slightly decreased by the treatment 
with CXH in mesangial cells. The high stability of CPT-Iα  protein in mesangial cells 
and hepatocytes might be very important in terms of FA homeostasis. This also 
indicates that the smallest changes in the CPT-Iα level, for example in 
inflammation, could lead to significant changes in metabolism, which in turn 
influence adaptation, survival or death of the cell.     
 
4.3   Effect of NO on CPT-Iα expression 
 
Among the many metabolic effects of NO, its role in modulation of FA metabolism 
has been demonstrated. The previous study by Gans, 2003 has shown that 
exogenously added NO donors such as DETA-NO were able to upregulate  CPT-Iα 
mRNA and protein expression in mesangial cells. Most importantly, it was shown 
that endogenously produced NO, which appears in high amounts after IL-1ß-
stimulated induction of iNOS (Kunz et al., 1994), is involved in an enhanced CPT-Iα    IV. Discussion 
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expression. The study presented here (also examined) the NO-mediated regulation 
of the CPT-Iα promoter activity in mesangial cells.  
 
4.3.1 Regulation of the CPT-Iα promoter by NO 
An approximately 2-fold increase in the CPT-Iα promoter activity was found after 
DETA-NO- and IL-1ß-stimulation of mesangial cells transfected with the CPT-Iα   
-4495/+19 promoter construct. In addition, the transfected mesangial cells were 
stimulated with palmitate as a positive control, which induced the activity of CPT-Iα  
-4495/+19 promoter construct 2-fold (For further discussions concerning palmitate 
action on CPT-Iα promoter see in "Effects of secretory Phospholipases A2", 
Chapter 4.5). Similar activation was obtained after stimulation with DETA-NO, IL-
1ß, or palmitate in mesangial cells transfected with -4495/+1240 containing the first 
intron  (data not shown).  These results suggested that (i) these two promoter 
constructs, without (-4495/+19) and with intron (-4495/+1240), might contain 
elements important for the NO-mediated promoter activation, and that (ii) the 
accumulation of CPT-Iα mRNA and protein levels might be the result of an increase 
in the transcription rate. Further studies including serial deletion of the promoter 
and/or site-directed mutations, are necessary to define regions within CPT-Iα 
promoter required for the gene induction.  
 
The CPT-Iα promoter is TATA-less, and basal expression is driven by transcription 
factor Sp1 and nuclear factor NF-Y (Steffen et al.,1999). Thus, it is similar to the 
promoters of other acyl transferases and enzymes involved in fatty acid oxidation. 
For instance, the medium-chain acyl-CoA dehydrogenase promoter is TATA-less 
with Sp 1 playing a prominent role in basal expression. The characterisation of the 
CPT-Iα promoter and identifying elements that regulate gene expression by NO 
and cytokines might lead to an understanding of the regulation of other renal 
acyltransferases and FA metabolism under inflammatory conditions.     
Moreover, to assess whether NO modifies CPT-Iα mRNA and protein stability, the 
half-life of CPT-Iα mRNA and protein should be determined after NO-donor or 
cytokine stimulation in the presence of the transcription inhibitor actinomycin D and 
inhibitor of protein synthesis CHX. To directly address whether changes in CPT-Iα 
expression induced by NO can result in a switch of substrate utilisation, the FFAs 
analysis and their oxidation rate in mesangial cells should  be further investigated.     IV. Discussion 
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4.3.2   Role of cGMP in the regulation of CPT-Iα  
 It is well known that many of the biological actions of NO, but not all, are mediated 
by the direct activation of soluble guanylyl cyclase (sGC) and the consequent 
increase in intracellular cGMP levels (Lucas at al., 2000). cGMP may modulate 
PKG, cGMP-gated ion channels, cGMP-regulated phosphodiesterases, and cyclic 
AMP-dependent protein kinases (Lucas at al., 2000). These are considered to be 
early and rapid mechanisms of NO signalling. However, the late phases which 
include such intercellular changes as release of secretory PLA2 (Rupprecht et al., 
1999) or regulation of lipid metabolites (Huwiler and Pfeilschifter, 2003) are 
mediated by alterations in gene expression (Pfeilschifter et al., 2001a; Pfeilschifter 
et al., 2001b). 
 
Recently, it was shown that in rat hepatocytes NO donors inhibited acetyl-CoA 
carboxylase (ACC) activity, the rate-limiting enzyme in the fatty acid biosynthesis 
pathway, which catalyses the formation of a potent CPT-Iα inhibitor malonyl-CoA. 
This inhibiton occurs via phosphorylation of ACC through cGMP-dependent protein 
kinase. Due to ACC inhibition by NO donors an increase in CPT-Iα activity was 
detectable (Garcia-Villafranca at al., 2002).  
 
In the present study, the involvement of NO/cGMP signaling pathway was further 
investigated at the CPT-Iα mRNA and protein expression level. The treatment of 
mesangial cells with ODQ  as an inhibitor of the sGC reduced the inducible effect of 
NO donor DETA-NO on CPT-Iα mRNA and protein expression. In addition, further 
experiments have shown that similar to DETA-NO, the sGC activator YC-1 was 
effective in induction of CPT-Iα protein level. These results show that the NO/cGMP 
pathway, at least in part, is crucial not only for the stimulation of CPT-Iα activity 
through inhibition of ACC and reduction of malonyl-CoA synthesis, but also for a 
direct induction of CPT-Iα mRNA and protein expression. Furthermore, similar to rat 
hepatocytes, in mesangial cells NO seems to mediate its action on CPT-Iα activity 
through the activation of sGC and production of intracellular cGMP. Thus, this 
combination might result in a dual control of CPT-Iα and fatty acid oxidation by 
increasing both the amount as well as the activity of the enzyme (Fig. 4.1). Both 
CPT-Iα induction and the downregulation of ACC and decrease in FA synthesis by    IV. Discussion 
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the NO/cGMP pathway, with a possible reduction in malonyl-CoA formation could 
participate in the stimulation of FA oxidation and presumably of ATP production.  
 
 
   Carcia-Villafranca J. et al., (2003) 
 
Figure 4.1   Schematic diagram of the involvement of NO/cGMP signalling pathway 
in the regulation of CPT-Iα activity, mRNA and protein expression. 
   
 
These results open the possibility that also in vivo, the NO/cGMP pathway may play 
a role in the control of lipid metabolism in liver and kidney. This knowledge could 
lead to a better understanding of the regulation of hepatic and renal metabolism 
and the mechanisms involved in inflammatory diseases of the liver and kidney 
where NO is drastically increased.  
 
4.3.3  Effect of proinflammatory cytokines on CPT-Iα expression in rat 
primary hepatocytes 
In the present study, I investigated whether NO upregulates the CPT-Iα protein and 
mRNA levels in rat hepatocytes. For this propose, rat primary hepatocytes were 
stimulated with DETA-NO for 24 hr. It was observed that the expression of CPT-Iα 
protein and mRNA was not altered at the concentration range of 0.1-0.5 mM. The 
same results were obtained at higher concentration (up to 1mM) and for earlier time 
points. Moreover, the stimulation of hepatocytes with IL-1ß did not cause any 
changes neither in endogenous NO production through activation of iNOS nor in 
CPT-Iα expression (data not shown). In contrast, the release of rat-sPLA2-IIA as a 
proinflammatoy enzyme was markedly elevated in supernatants from the    IV. Discussion 
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hepatocyte cell culture stimulated with DETA-NO in dose-dependent manner 
suggesting that hepatocytes responded to the treatment with the NO donor during 
the time course of 24 hr.  
 
There are a number of studies carried out in primary rat hepatocytes, which have 
shown the role of cytokines in stimulation of iNOS and NO production. For instance, 
Sewer and Morgan (1997) demonstrated that iNOS mRNA and subsequently NO 
release was induced after 24 hr incubation with pro-inflammatory agents such as  
IL-1ß, TNFα and LPS. However, in this study the rat hepatocytes were cultured in 
medium and plating conditions different from those used in the present work (in 
Sewer and Morgan’s experiments, the primary hepatocytes were cultured for 5-7 
days with Waymouth's medium). Thus, the apparent discrepancies in endogenous 
NO induction through cytokine could be attributed to the culture conditions.  
 
Furthermore, the regulation of CPT-Iα expression might require much longer 
stimulation time, and thus, experiments in vivo could be more suitable to study long-
term regulatory effect of NO donors. The model in our study has its limitations as 
the survival time of hepatocytes as primary cell cultures was rather short. 
Hepatocytes loose their differentiated phenotype after 2 days of culture, and the 
cells tend to detach from the culture dishes. The reason for this degenerative 
course is uncertain, but three factors must principally be considered to be of 
importance, namely, the absence of other liver cells, the matrix used for plating the 
cells and the composition of the medium (Dich et al.,1988). Despite this, in the 
present study the primary hepatocyte cultures were suitable for investigation of 
short-term regulatory effects on CPT-Iα regulation. 
 
4.4   Hypoxia 
 
4.4.1   Regulation of CPT-Iα by hypoxia 
Hypoxia induces transcriptional regulation of a wide variety of genes encoding 
proteins necessary for cellular and physiological adaptation, including alterations  in 
metabolic events and energy consumption. For example, several genes encoding 
glycolytic enzymes are activated leading to a switch from ß-oxidation to glycolysis. 
While strong evidence exists that the hypoxia-induced activation of glycolytic 
enzymes is mediated by the HIF-Iα (Semenza et al., 1994; Semenza et al., 1996),    IV. Discussion 
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no information is available on the mechanisms involved in the modulation of FA 
metabolism and expression of lipolytic enzymes such as CPT-Iα or mHMG-CoA 
synthase    
 
In the present work, the effect of hypoxic conditions on CPT-Iα mRNA and protein 
expression in the rat mesangial cells and hepatocytes was investigated.  
In the first series of experiments it was shown that the incubation of mesangial cells 
with CoCl2, which mimics hypoxia, leads to an increase in CPT-Iα mRNA and 
protein expression. With 100 µM CoCl2, the CPT-Iα mRNA level already started to 
increase after 2 hr and  remained elevated up to 24 hr. The treatment for 24 hr with 
concentrations of CoCl2  between 50 and 200 µM showed a dose-dependent 
induction. The incubation with higher concentration (400 µM) caused a slight 
decrease, and the incubation with 100 µM CoCl2  for longer time (between 24 and 
48 hr) resulted in a decrease in mRNA levels which could be explained by the 
toxicity and apoptotic effect of CoCl2 (Kakinuma, et al., 2001; Araya et al., 2002). In 
contrast to the mRNA level, CPT-Iα protein accumulated in a manner independent 
of the concentrations used.  
 
An even more greater difference between effects of CoCl2 on protein and mRNA 
level was seen in the next series of experiments performed with rat primary 
hepatocytes. Here, the treatment with 200 µl CoCl2 caused a significant induction of 
CPT-Iα protein, while CPT-Iα mRNA level decreased. The reason for this 
discrepancy between mRNA and protein expression is unknown. One explanation 
might be that in renal cells of hypoxic rats, swelling, rupture of inner and outer 
membranes, and leakage of mitochondrial matrix  are induced (Benitez-Bribiesca et 
al., 2000). Since CPT-Iα is located in the mitochondrial outer membrane, the 
isolation and detection of CPT-Iα protein by Western blot analysis may be 
complicated because of these ultrastructural changes of mitochondria which may 
also have occurred in the experiments with rat mesangial cells and hepatocytes.  
 
While exposure to hypoxia led to the clear accumulation of CPT-Iα protein in both 
the mesangial cells and hepatocytes, the upregulation of detectable CPT-Iα mRNA 
in the mesangial cells, was not seen in the hepatocytes. This difference in mRNA 
expression between mesangial cells and hepatocytes might mirror the tissue    IV. Discussion 
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specificity described in an earlier study, which demonstrates that regulatory factors 
of CPT-Iα expression such as development, hormones and diet have different 
effects in liver and heart (Cook et al., 2001).  
 
These results showed that CPT-Iα in mesangial cells and hepatocytes is affected 
by the hypoxia mimicking CoCl2. However, the treatment with CoCl2 triggers not 
only hypoxia and activation of HIF-Iα or  HIF-2α, but also other physiologically 
significant signalling systems. For instance, CoCl2 increases expression of heat 
shock proteins hsp 65 and hsp 72 in keratinocytes (Nordlind, 2002). Furthermore, 
CoCl2 induces apoptosis via mitochondrial pathway thereby releasing cytochrome c 
and formation of highly reactive oxygen radicals, which may contribute to 
mitochondrial damage (Clyne et al., 2001; Araya et al., 2002). Therefore, the 
treatment with CoCl2 has many other effects, which are not related to hypoxia but 
may even dominate the hypoxia effects.  
 
Based on this information, in the next series of experiments cell culture incubation 
was carried out using a gas mixture containing low percentage of oxygen (1% or 
3%). These experiments were done in comparison to the treatment with CoCl2 and 
the iron chelator DFO. The results show that the CPT-Iα mRNA and protein levels 
were increased in response to hypoxia (3% O2) as well as to CoCl2, or DFO in the 
mesangial cells. This result suggests that similar mechanisms are involved in these 
three models of hypoxia-mediated activation of CPT-Iα expression in the mesangial 
cells. 
 Because many initial observations showed that hypoxia results in inhibition of FA 
oxidation, the further investigation should be performed to determine the 
relationship between the CPT-Iα expression and the rate of ß-oxidation under 
hypoxic condition. Despite of the influence of hypoxia on CPT-Iα expression, the 
rates of ß-oxidation during hypoxia might be affected by several steps involved in 
fatty oxidation including the cellular uptake, activation of FA or enzymes of the ß-
oxidation spiral.   
 
By using hepatocyte culture conditions with a lower percentage of oxygen (1%) the 
clear downregulation of CPT-Iα mRNA expression was achieved which is 
consistent with observations of previous studies showing a decrease in FA-
oxidation and a switch to glycolysis as source of energy  during hypoxic condition    IV. Discussion 
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(Huss, et al., 2001). The downregulation of CPT-Iα mRNA level through exposure 
to more pronounced hypoxia (1% O2) and, on the other hand, induction in response 
to CoCl2 and DFO suggest that different regulatory mechanisms of both forms of 
hypoxia might be responsible for the differences in CPT-Iα expression in 
hepatocytes.  
 
Moreover, these preliminary experiments show that alterations in the oxygen 
content of the gas mixture (1%-3% O2) may trigger different effects on CPT-Iα level. 
Therefore, further studies are needed to explore the hypoxia-mediated effects on 
CPT-Iα expression in relation to the oxygen content. 
    
Several mechanisms could be responsible for the regulation of CPT-Iα under 
hypoxic condition. A previous study has shown that in cardiac myocytes, hypoxia 
suppresses up-regulation of CPT-Iß in response to LCFA via PAPRα/RXR 
pathway, where the nuclear protein level of RXRα is reduced and thereby, the 
LCFA-induced transcription of CPT-Iß gene is decreased  (Huss  et al., 2001). It 
could be predicted that signalling through RXR-dependent pathways would similarly 
affect CPT-Iα in mesangial or liver cells, as in these cells PPARα also plays a 
critical role in the regulation of gene expression (Scholz-Pedretti et al., 2002, 
Lawrence et al., 2001; Eberhardt et al., 2000; Eberhardt et al., 2002; Hsu et al., 
2001). Another mechanism that might regulate CPT-Iα is the HIF-dependent 
transcriptional change in gene expression. Computer analysis of the promoter 
sequence of CPT-Iα gene reveals a HRE consensus sequence (ACGTGC) located 
at -6245/-6239 bp upstream the start site of transcription, which could be able to 
bind HIF-Iα or HIF-2.  To investigate the possible role of the putative HRE and 
PPRE in regulating CPT-Iα gene expression in mesangail cells and hepatocytes, 
further transfection experiments under hypoxic conditions should be carried out 
using constructs with mutations in the PPRE and HRE sites. 
 
Taken together, the results show the complexity of CPT-Iα regulation during   
hypoxia, and leaving many open questions.   
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4.4.2   Regulation of mHMG-CoA synthase by hypoxia 
In the next series of experiments, the expression of mHMG-CoA synthase mRNA 
was investigated in mesangial cells and hepatocytes under hypoxic conditions. As 
shown in Fig. 3.13, the exposure of mesangial cells to 3% O2, CoCl2 or DFO leads 
to a reduction of mHMG-CoA synthase mRNA expression. A similar decrease was 
observed in hepatocytes using 1% O2, CoCl2 or DFO. Interestingly, in hepatocytes 
1% oxygen decreased mHMG-CoA synthase mRNA at an earlier time point (after 4 
hr incubation) as compared to the chemical compounds. It was reported that 
allocation of acetyl-CoA to either ketogenesis or the Krebs cycle (a universal 
metabolic pathway in which the acetyl group of acetyl-CoA is oxidized to two CO2, 
and four pairs of electrons are transferred to coenzymes) is controlled by the 
mitochondrial ATP concentration. Furthermore, an insufficient oxygen supply and 
ATP production reduce the level of ketone bodies in patients suffering from 
respiratory dysfunction (Tsubokawa et al., 1998). Thus, the reason for the rapid 
response to hypoxia might be explained by a fast depletion of ATP production, 
which is strongly regulated by oxygen supply. Moreover, it is likely that a decrease 
in mitochondrial ATP production rate after exposure of the cells to CoCl2 or DFO 
might be secondary to the changes in the activity and/or expression of factors in 
oxygen sensing (e.g. HIF-Iα). This might explain the delayed effect of the chemical 
compounds (after 24 hr) in comparison to environmental hypoxia (1% oxygen). 
 
  The observation of inhibitory effect of hypoxia on mHMG-CoA synthase mRNA 
expression suggests that ketone body building might also be decreased in 
mesangial cells and hepatocytes. To explore this hypothesis, the ketone body 
content in mesangial cells and hepatocytes exposed to hypoxia should be analysed 
in future studies. Moreover, nothing is known about the regulatory mechanism of 
hypoxia-mediated downregulation of mHMG-CoA synthase protein expression as 
there are currently no antibodies available for this protein.  
 
4.5  Effects of secretory Phospholipases A2 
 
sPLA2s, as extracellar and circulating enzymes, play an important role in direct or 
indirect stimulation of the release of arachidonic acid and other free FAs and 
prostaglandins under inflammatory conditions (Schalkwijk et al., 1991; Pfeilschifter 
et al., 1993; Pfeilschifter et al., 1997) thereby providing a rapid as well as sustained    IV. Discussion 
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increase in substrate for the CPT-Iα. Moreover, it was speculated that a drastic 
increase in sPLA2-released free FAs has an effect on CPT-Iα expression, as it is 
known from earlier studies that free FAs regulate the transcription of CPT-Iα in rat 
hepatocytes and another cell types (McGarry and Foster, 1980; Chatelain et al., 
1996). 
Therefore, the effects of extracellular sPLA2s on the CPT-Iα expression were 
investigated.  
 
Furthermore, several diseases are associated with high levels of extracellular 
sPLA2 which itself can induce significant increases in proinflammatory cytokines 
such as TNFα, IL-1 and IL-6 (Granata et al., 2003) and chemokines (Beck GCh et 
al., 2003). Moreover, initial observations demonstrated that TNFα and IL-1ß are 
potent inducers of sPLA2 mRNA expression (Pfeilschifter et al., 1997; Couturier et 
al., 1999; Scholz-Pedretti et al., 2002; Beck et al., 2003). Together, cytokines and 
sPLA2 potentiate each others synthesis, thereby creating an amplification loop for 
the progression of inflammatory responses. The role of extracellular sPLA2s on 
CPT-Iα expression was completely unknown and was studied in the present work  
in rat mesangial cells and primary hepatocytes.  
 
It was shown that in mesangial cells, exogenously added h-sPLA2-IIA as well as 
TNFα enhanced CPT-Iα protein expression which was also potentiated by co-
treatment with both agents. However, in rat primary hepatocytes the h-sPLA2-IIA-
stimulated increase in CPT-Iα protein expression was no longer potentiated by 
TNFα. This difference in regulation of CPT-Iα protein expression between 
mesangial cells and hepatocytes might be tissue specific.  
 
Furthermore, it was investigated as to whether the sPLA2 or TNF-α-induced 
increase in CPT-Iα was derived from de novo protein biosynthesis. The 
coincubation of TNFα or h-sPLA2-IIA with the protein synthesis inhibitor CHX 
resulted in a slight decrease of CPT-Iα protein level in comparison with incubation 
with TNFα or h-sPLA2-IIA alone, suggesting that TNFα or h-sPLA2-IIA stimulate 
CPT-Iα protein synthesis. Interestingly, in this experiment CHX alone induced CPT-
Iα protein expression. One could speculate that CHX inhibits the protein synthesis    IV. Discussion 
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of a regulatory protein working as a repressor of CPT-Iα. Its disappearance may 
then lead to an increased synthesis of CPT-Iα protein.  
 
The stimulatory effect of h-sPLA2-IIA as well as of further exogenously added 
sPLA2s and TNFα was also demonstrated in mesangial cells at mRNA level. 
Induction of CPT-Iα mRNA expression with these sPLA2s was potentiated by 
costimulation with TNFα, which correlates with the increases in CPT-Iα protein. 
 
The mode of sPLA2s action on CPT-Iα expression is not clear. One possibility may 
be an activation of PPARα via the released lipid metabolites. As natural ligands of 
PPARα (Lee et al., 2003, Corton et al., 2000), fatty acids and eicosanoids may 
activate CPT-Iα gene expression by recognition of PPRE exhibited in the proximal 
CPT-Iα promoter (-2859/-2846) (Louet et al., 2001[a; b]). Thus, in mesangial cells 
transfected with two different CPT-Iα promoter constructs (-4495/+1240 containing 
first intron, or -4495/+19) containing PPRE, exogenous sPLA2s and TNFα as well 
as palmitate and the PPARα activator WY14.643 increase the promoter activities 
up to 2-fold, whereas the -210/+19 promoter construct was not activated. The  
-210/+19 promoter construct does not include PPRE but contains binding sites for 
other transcription factors such as CCAAT box element, NF-Y and Sp1 sites, which 
as shown in a previous study, regulates basal transcription of the CPT-Iα promoter 
(Steffen et al., 1999).  
 
In contrast to the results at protein and mRNA level, the costimulation of h-sPLA2-
IIA with TNFα has no potentiating effect on the promoter activity, suggesting that 
either both compounds use the same transcription factors to activate CPT-Iα 
transcription, or that the additive effect of their combination at the protein level may 
occur through a post-transcriptional mechanism. 
 
To support the hypothesis that PPARα might be involved in the induction of CPT-
Iα gene expression by FAs released through exogenously added sPLA2s and also 
by rat sPLA2s endogenously produced after cytokine treatment, further studies have 
to be done. First, FAs, which are specifically released by sPLA2s and cytokines in 
mesangial cells and hepatocytes and which might be active in the regulation of 
gene transcription, should be characterised. Next, it must to be confirmed that these    IV. Discussion 
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FAs could act as PPAR ligands. Therefore, rat CPT-Iα promoter construct 
containing mutated PPAR binding sites should be cloned  and  the effects of 
exogenously added sPLA2s and TNFα on the promoter activity should be analysed 
in the absence or presence of the functional PPAR binding sites.  
 
Until recently, it was generally thought that FA regulation of gene transcription was 
a simple PPAR-mediated process. However, recent publications show that various 
sensors can relay the transcriptional effects of FAs either through direct binding to 
DNA (PPAR, liver x receptor LXR, hepatic nuclear factor 4 HNF-4α) or via 
modulations in the abundance of other transcription factors (sterol regulatory 
element binding protein SREBP, carbohydrate responsive element binding protein 
ChREBP) in an indirect manner. The list of potential transcription factors involved in 
FA-mediated gene expression is probably not yet complete (Pégorier et al., 2004). 
For example, it was shown that a DNA sequence responsible for FA-induced  
CPT-Iα gene expression in rat hepatocytes was located in the first intron of the 
gene and analysis of the intronic sequence reveals no consensus sequences, 
suggesting that other transcription factors could transduce the FA signals to DNA 
(Louet et al., 2001). In contrast in this study, luciferase activity in mesangial cells 
transfected with -4495/+19 promoter construct, which did not include the first intron, 
was stimulated with palmitate (as well as sPLA2s and TNFα ) in the similar manner 
as it was seen with cells transfected with the promoter construct containing first 
intron. This discrepancy with previous studies could be due to the tissue specificity 
of the FAs in the regulation of gene expression.     
 
Exogenously added sPLA2 and cytokines, such as IL-1ß and TNFα, enhance the 
activity of cytosolic PLA2 (cPLA2). cPLA2 mainly regulates AA release from 
membrane phospholipids (Pfeilschifter J, 1989; Pfeilschifter J, 1994), which is the 
rate-limiting step in the formation of prostaglandins. Lipid metabolites produced by 
the action of cPLA2  can activate sPLA2 gene expression and its secretion and thus, 
potentiate the release of a broad spectrum of free fatty acids under inflammatory 
conditions (Beck et al., 2003). This feed back regulation between exogenously 
added and cytosolic phospholipases and thereby potentiated release of FAs might 
be associated with amplification of sPLA2 and cytokine effects on CPT-Iα activation.  
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The mechanism of such cross-talk between PLA2s remains poorly understood. But  
there is evidence that activation of cPLA2 through sPLA2s and cytokines occur, at 
least partly, by a phosphorylation of cPLA2 through mitogen-activated protein kinase 
(MAPK) (Huwiler et al., 1997; Mounier et al., 2004). Thus, the regulation of CPT-Iα 
expression by stimulation with sPLA2s and cytokines may also involve the activation 
of the MAPK pathway (Fig 4.2). Indeed in rat mesangial cells, MAPK inhibitors PD 
98059 and U0126 were able to block the enhancing effect of h-sPLA2–IIA and 
TNFα on CPT-Iα protein expression. Moreover, in the same experiment the TNFα-
induced secretion of endogenously expressed rat-sPLA2-IIA  was significantly 
blunted by PD 98059 and U0126 in mesangial cells. The results of this study 
suggested that activation of CPT-Iα by sPLA2 and TNFα might involve the MAPK 
pathway, however, further investigation of this pathway in the regulation of FA 
metabolism are necessary. A number of conditions such as inflammation which 
evokes metabolic stress are known to activate MAPK and the outcome of studies 
with MAPK inhibitors, which prevent the action of cPLA2 and sPLA2s on metabolic 
process, might be of significant interest. 
 
 
 Figure 4.2   Schematic diagram of the contribution of the MAPK signalling pathway 
to the regulation of CPT-Iα expression by sPLA2s and TNF. 
 
It is well known that ketone body synthesis and activation of mHMG-CoA synthase 
expression, which catalyses rate-limiting steps of ketogenesis pathway, is 
increased by stimulation with FAs via PPRAα (Rodriguez et al., 1994). Therefore, it 
was investigated whether enhanced FAs levels produced by sPLA2s and TNFα     IV. Discussion 
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affects the mRNA expression of mHMG-CoA synthase. The results show that after 
treatment of mesangial cells with these agonists, the mRNA expression of mHMG-
CoA synthase displayed a different pattern in comparison to CPT-Iα (3.22). The 
mRNA mHMG-CoA synthase was dramatically upregulated through various 
exogenous sPLA2s only by costimulation with TNFα, suggesting that regulation of 
this protein requires not only sPLA2  activity but also TNF-α-activated signalling 
pathways. To study, whether the increase in mHMG synthase mRNA level is 
accompanied by increased gene transcription, protein expression and enzymatic 
activity, further studies at the promoter and protein level or determination of ketone 
body formation are required.  
 
The control of ketogenesis by substrate availability (acetyl-CoA) after entry of FAs 
into mitochondria, which is regulated by CPT-Iα, has been extensively reviewed 
(McGarry and Braun 1997; Hegardt, 1999). Therefore, the increase in the mHMG-
CoA synthase mRNA level may be, in part, secondary to increased CPT-Iα 
expression. It might be speculated that the enhanced CPT-Iα gene and protein 
expression induced by sPLA2s and TNFα contribute to ß-oxidation and production 
of acetyl-CoA as a substrate for mHMG-CoA synthase and thus, stimulate the 
ketogenic pathway. To prove this hypothesis it would be necessary to study the 
effect of specific CPT-Iα inhibitors such as etomoxir (Lopaschuk et al., 1988) 
 
The data indicate that under inflammatory conditions, extracellular sPLA2 activity 
might be a potent regulator of lipid and energy homeostasis because sPLA2: 
a) produces increased amounts of free FAs and their metabolites (as it is known 
from previous studies); b) enhances CPT-Iα expression and thereby increases the 
transport of FAs to the mitochondria for oxidation; c) activates the mHMG-CoA 
synthase mRNA expression and presumably ketogenesis. In addition, it would be 
beneficial to support these data with measurements of FAs metabolites and high 
energy phosphates (ATP, ADP) or by evaluating the rate of fatty acid oxidation in 
mesangial cells and primary hepatocytes. 
 
 
 
    IV. Discussion 
      89
4.6   Clinic  relevance 
 
Regulation of the gene expression of CPT-Iα or mHMG-CoA synthase which are 
involved in lipid metabolism is of significant physiological and clinical interest and 
should be considered in drug development and therapeutic practise in the treatment 
of diseases such as hyperlipidemia, atherosclerosis, and obesity. It is well known 
that an inhibition of the carnitine palmitoyltransferase system and consequently, the 
transport of long-chain fatty acids across mitochondrial membranes by certain 
medication or pathology (e.g. ischemia/hypoxia, inflammation) may lead to dramatic 
changes in energy homeostasis and thus culminate in life threatening conditions. 
For example, the therapy with adriamycin (ADR), which inhibits the CPT system, 
leads to ADR toxicity manifesting in cardiomyopathy as a result of globally 
impairment of fatty acid oxidation (Yoon et al., 2003;). Furthermore, determination 
of CPT-Iα as the rate-limiting step of ketogenensis (in addition to mHMG-CoA 
synthase) led to the observation that inhibition of this enzyme may cause a 
significant downregulation of mHMG-CoA synthase and depression of ketone body 
production, a major substrate for extrahepatic organs such as the brain. The 
nervous system has one of the highest rates of oxygen metabolism in the body and 
lacks tissue oxygen stores, depending on a continuous exogenous supply of 
oxygen from the liver (Blazquez et al., 1999).  
  
Fatty acids have been identified as one of the main energy substrates used by the 
mammalian kidney. Mitochondrial fatty acid ß-oxidation, which allows high yields of 
ATP production, plays an essential role in supporting kidney reabsorptive functions, 
as evidenced by the effects of mitochondrial fatty acid utilisation blockers, which 
induce marked impairments in proximal tubule reabsorption (Wirthensohn and 
Guder, 1983). Also, the activation of CPT-Iα in liver might be of critical importance 
because of an increased FA oxidation and ATP production, which is necessary for 
proteins used in killing of pathogens and repair mechanisms in inflammatory renal 
and hepatic diseases. Thus, modulation of the expression of CPT-Iα might have an 
important role in preservation of kidney and liver during inflammation.  
 
The next important question concerns involvement of CPT-Iα and mHMG-CoA 
synthase in FAs degradation. Elevated level of free FAs through induction of 
sPLA2s during inflammation (Murakumi and Kudo 2004) might potentiate    IV. Discussion 
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pathological process. Some diseases such as atherosclerosis, diabetes or certain 
forms of cancer are associated with the enhanced amount of the FAs which 
secondarily contribute to their effects on phospholipid composition of membrane or 
on the expression of specific genes. 
For instance, it was shown that a chronically elevated level of free FA can cause 
apoptosis of pancreatic ß-cells as a result of the formation of ceramides, which 
induce nitric oxide-dependent cell death (Cnop et al., 2001; Schimabukuro et al., 
1998). Furthermore, recent studies show that alcohol-mediated  accumulation of 
free FAs potentiate liver injury and fatty liver (Fischner et al., 2004). Thus, from the 
effects of sPLA2s on CPT-Iα and mHMG-CoA synthase in renal mesangial cells and 
hepatocytes, it might be concluded that a decrease in fatty acids protects liver and 
kidney from lipid accumulation and further pathological consequences.  
  
Further studies will help to delineate whether PPARα and MAPK might play an 
regulatory role in triggering the fatty acid utilisation by CPT-Iα under inflammatory 
conditions in organs such as kidney or liver which strongly depend on FAs 
metabolism to ensure their energy homeostasis. In this respect, the identification of 
effects of the PPAR and  MAPK activators and/or specific inhibitors of these target 
molecules may lead to a better understanding of the complete role of PPARs and 
MAPKs pathway in the control of lipid metabolism (Guan and Breyer, 2001; 
Englisch and Cobb, 2002).    V. Summary  
    91
V 
Summary 
___________________________________ 
 
 
Energy substrate utilisation rates are regulated during development and in 
response to physiological and pathophysiological stimuli. Injury and inflammation 
result in marked changes in whole body lipid metabolism, including free fatty acid 
oxidation (Show et al., 1989). The regulation of fatty acid oxidation is most 
dependent on the enzyme carnitine palmitoyl transferase-I (CPT-I), which exists in 
two isoforms,  hepatic CPT-Iα and muscle CPT-Iß isoform, and which catalyses the 
initial reaction in the mitochondrial import of long-chain fatty acids. This is a tightly 
regulated step in the cellular fatty acid utilisation pathway to provide ATP. In concert 
with mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHMG-CoA 
synthase), CPT-Iα is also responsible for the production of ketone bodies, the 
alternative fuel for extrahepatic organs. 
 
The aim of this thesis was to investigate the role of CPT-Iα under different 
inflammatory conditions, using pharmacologically active agents like nitric oxide 
donors, hypoxia-mimicking substances and exogenous phospholipases A2.   
 
This project is divided into four parts. The first part of the experimental work was 
devoted to the determination of the optimal Western blot conditions using a 
polyclonal antibody against CPT-Iα in rat mesangial and primary liver cells. The 
stability and concentration of CPT-Iα protein in these two cell cultures  was also 
characterised. 
 
In a previous thesis performed by Dr. Annette Gans (2003), a  stimulating effect of 
nitric oxide on the CPT-Iα protein and mRNA expression in rat mesangial cells was 
described. Thus, in the second part of the  work, based on this thesis, studies were 
carried out to investigate the effect of NO on the CPT-Iα promoter activity.    V. Summary  
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Moreover, a possible involvement of NO/cyclic GMP pathway on the regulation of 
CPT-Iα expression was explored. 
The data show that NO is able to increase luciferase activity of -4495/+19 CPT-Iα  
promoter construct in mesangial cells correlating with its activation at protein and 
mRNA level obtained in previous study.  
The NO-induced upregulation is reversed by the soluble guanylate cyclase sGC 
inhibitor, ODQ, at protein and mRNA level. Moreover, the sGC activator YC-1 was 
able to increase CPT-Iα protein level. These results suggest that in rat mesangial 
cells the cGMP pathway is possibly involved in the induction of CPT-Iα mRNA and 
protein expression through NO.   
  The third part of this project includes the investigation of the effect of hypoxic 
conditions on CPT-Iα and mHMG-CoA synthase in rat mesangial and primary rat 
liver cells.  
Two models of hypoxic culture conditions were used in this study: 
1) Exposure of the cells to the transition metal Co
2+ or to the iron chelator   
desferrioxamine during normoxia. 
2) Culturing cells in an air-tight chamber, which was infused by a gas mixture 
containing 3% or 1% O2.   
Hypoxia mimic Co
2+ or desferrioxamine as well as 3% O2  hypoxia were able to 
upregulate CPT-Iα protein and mRNA expression in rat mesangial cells. In rat 
hepatocytes Co
2+ induced CPT-Iα at protein level and did not cause changes at 
mRNA level, whereas the expose to more severe hypoxia (1% O2) markedly 
decreased and treatment with desferrioxamine increased CPT-Iα mRNA. 
Furthermore, Co
2+ and desferrioxamine and 3% O2  hypoxia were also able to 
decrease mHMG-CoA synthase mRNA level in rat hepatocytes. These results 
suggest that in regulation of CPT-Iα and mHMG-CoA in rat mesangial cells and 
hepatocytes by the above mentioned models of hypoxic culture conditions different 
regulatory pathways are affected. 
 
The fourth part of the thesis was devoted to the effect of exogenously added 
secreted phospholipases A2 (sPLA2s) on CPT-Iα expression at the protein, mRNA 
and promoter level. This project was stimulated by a recent observation that 
sPLA2s, when released under inflammatory conditions into the extracellular space,  
cleave fatty acids from glycero-phospholipids, which then may trigger an    V. Summary  
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upregulation of CPT-Iα expression. In addition, this part of the project includes 
preliminary studies on the molecular mechanisms of sPLA2s on mHMG-CoA 
synthase expression.   
The treatment with exogenously added sPLA2s and TNFα, which are known to 
amplify expression of endogenous sPLA2-IIA, led to induction of CPT-Iα at protein, 
mRNA and prompter level in mesangial cells and to protein level in hepatocytes.  
This effect was reduced by co-treatment of mesangial cells with mitogen-activated 
protein kinase (MAPK) inhibitors PD 98059 and U0126, thus suggesting that 
sPLA2s-mediated induction of CPT-Iα might, at least partly, involve MAPK pathway. 
Moreover, the also mHMG-CoA synthase mRNA level was markedly enhanced  by 
the costimulation of h-sPLA2-IIA with TNFα. 
In summary, this work demonstrated that the CPT-Iα is a carefully regulated protein 
that plays a critical role in response to inflammatory condition.  
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VII 
Appendix 
___________________________________ 
7.1 Abbreviations 
 
 
AA   arachidonic acid 
AMPK  AMP-activated protein kinase 
BSA bovine  serum  albumin 
CHX cycloheximide 
CPT-I                carnitine palmitoyltransferase I 
cPLA2  cytosolic phospholipase A2 
DFO disferrioxamine 
FA fatty  acid 
HIF-1α  hypoxia-inducible factor -1α 
HMG-CoAs 3-hydroxy-3-methylglutaryl-CoA  synthase 
HRE  hypoxia-responsive element  
HSPG  heparan sulfate proteoglycan  
IL interleukin 
iNOS  inducible NO synthase 
kbp kilobase  pair(s) 
LCFA   long-chain fatty acid  
LPS lipopolysaccharide 
MAPK   mitogen-activated protein kinese 
mHMG-CoAs mitochndrial  mHMG-CoAs 
NAD   nicotinamide 
NF-κB nuclear  factor-κB 
NF-Y nuclear  factor-Y 
NO nitric  oxide   
PAF platelet-activating  factor     VII.  Appendix 
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PBS phosphate-buffered  saline 
PIPES piperazine-N,N’-bis(2-hydroxypropanesulfonic  acid) 
PKC  protein kinase C 
PP peroxisome  proliferator 
PPARα peroxisome  proliferator-activated  receptor  α 
PPRE PPAR  response  element 
rMC  rat Mesangial cell 
RT  room temperature (20-25°C) 
RXR  retinoic X receptor 
SDS-PAGE             sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
sGC  soluble guanylyl cyclase  
sPLA2  secreted phospholipase A2 
TBS Tris-buffered  saline 
TBST    Tris-buffered saline (TBS) supplemented with 0,05%Tween 20 
TNFα   tumor necrosis factor-α 
VEGF  vascular endothelial growth factor 
WAT  white adipose tissue 
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7.4 Deutsche  Zusammenfassung 
 
Fettsäuren erfühlen vielfältige Funktionen im Organismus. Sie sind 
Brennstoffmoleküle, intrazelluläre Signalmoleküle und sie stellen wichtige 
Bestandteile biologischer Membranen dar.   
Der Abbau von Fettsäuren findet im Mitochondrium statt. Da langkettige Fettsäuren 
nicht ohne weiteres die  Mitochondrienmembran überwinden können, benötigen sie 
einen Transportmechanismus, das so genannte Carnitin-Palmitoyltransferase-
System. Zu diesem System gehören die Carnitin-Palmitoyltransferase-(CPT)-I an 
der Aussenseite, und die CPT-II an der Innenseite der Mitochondrienmembran, 
welche beide maßgeblich am Transport der Acylgruppe der Fettsäuren in Form von 
Acyl-CoA in das Innere des Mitochondriums beteiligt sind. CPT-I ist bei diesem 
Transport der geschwindigkeitbestimmende Schritt und existiert in zwei  Isoformen, 
eine vom hepatischen (CPT-Iα) und einem vom muskulären Typ (CPT-Iß).   
Ziel dieser Arbeit war die Untersuchung der CPT-Iα in kultivierten Mesangiumzellen 
der Rattenniere und primären Hepatocyten der Rattenleber unter Bedingungen, die 
an der Entstehung und Progression entzündlicher Prozesse in diesen Organen 
beteiligt sind:  
1) Hypoxie, 
2) Stickstoffmonoxid (NO), 
3) extrazelluläre sekretorische Phospholipasen A2  (sPLA2). 
Die Wahl der o.g. Bedingungen wurde aus folgenden Gründe gewählt: 
Viele Entzündungsreaktionen zeichnen sich durch eine massive Produktion von NO 
und einer erhöhten Sekretion von sPLA2 sowie durch eine lokale 
Durchblutungsstörung des Gewebes aus, was zu einer Sauerstoff-Unterversorgung 
der Zellen führt. Die CPT-Iα ist zudem mit einem Schlüsselenzym der Ketogenese, 
der mitochondrialen Hydroxymethylglutaryl-CoA-Syntase (mHG-CoA-Syntase) 
gekoppelt. Daher wurde die Wirkung von Hypoxie und exogenen sPLA2s auch auf 
die mHG-CoA-Syntase Expression untersucht.  
Diese Arbeit ist in vier Teile gegliedert.  
1.) Zunächst wurden optimale Bedingungen erarbeitet, die mit einem spezifischen 
Antiserum mittels Western-Blot-Analyse erfolgreich zur Detektion des CPT-Iα 
Proteins in den verwendeten Zellsystemen führten. Zudem wurde mit Hilfe des 
Proteinsynthese-Inhibitors Cycloheximid keine Abnahme der CPT-Iα     VII.  Appendix 
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Proteinmengen festgestellt. Unter unstimulierten Bedingungen scheint dieses 
Protein demnach einem langsamen ‚turn-over’ zu unterliegen. 
2.) In einer früheren Arbeit in Mesangiumzellen wurde gezeigt, dass durch DETA-
NO- und Interleukin 1ß (IL-1ß)-Stimulation freigesetztes NO einen stimulierenden 
Effekt auf die CPT-Iα-Protein und -mRNA Expression aufweist.  
In der vorliegenden Arbeit wurde nun der NO-stimulierende Effekt auf den CPT-Iα− 
Promotor untersucht, um die Regulation der Transkription dieses Enzyms zu 
untersuchen. Es wurde festgestellt, dass sowohl DETA-NO als auch IL-1ß eine 
signifikante Steigerung der Promotor-Aktivität des -4495/+19  CPT-Iα  
Promotorkonstrukts induzieren, die mit dem Anstieg der mRNA- und 
Proteinexpression korreliert. Bezogen auf frühere Untersuchungen in Ratten-
Hepatocyten zur Beteiligung der cytosolische Guanylatcyclase (cGC) und 
cyclischem Guanosinmonophosphat (sGMP) an der CPT-Iα Aktivität, wurde nun 
auch in Mesangiumzellen die Rolle des NO/cGMP-Signal-Weges in der Regulation 
des CPT-Iα untersucht. Es zeigte sich, dass die NO-induzierte CPT-Iα Expression 
durch den sGC-Inhibitor ODQ gehemmt werden konnte. Zudem induzierte YC-1 
(ein sGC–Aktivator) die CPT-Iα Proteinexpression. Daraus konnte gefolgert 
werden, dass in Mesangiumzellen das unter proinflammatorischen Bedingungen 
gebildete NO die Expression der CPT-Iα über die Aktivierung der cGMP-
vermittelten Signaltransduktion reguliert. 
3.) Zur Untersuchung des Einflusses von Hypoxie auf die CPT-Iα und mHMG-CoA 
Synthase-Expression in Rattenmesangiumzellen und -hepatocyten wurden zwei 
verschiedene Hypoxie-Modelle gewählt: 
a)  Stimulation der Zellen mit CoCl2
 oder mit dem Fe
2+-Chelator Desferrioxamin 
unter normoxischen Bedienungen oder 
b) Kultivierung der Zellen in einer luftdichten Kammer, die mit einer 3%igen oder 
1%igen O2-Mischung begast wird. 
In Measangiumzellen wurde die CPT-Iα Protein- und mRNA- Expression durch 
CoCl2, Desferrioxamin und 3% O2- vermittelte Hypoxie verstärkt. In Gegensatz dazu 
erhöht CoCl2 in den Hepatocyten nur die CPT-Iα Proteinmenge, während die 
mRNA-Expression unbeeinflusst blieb. Dagegen wurde in den Hepatocyten die 
CPT-Iα mRNA-Expression durch Desferrioxamin verstärkt und durch 1% O2 
Hypoxia gehemmt. Solche unterschiedliche Auswirkungen von zwei hypoxischen 
Modellsystemen auf die CPT-Iα Protein- und mRNA-Expression in     VII.  Appendix 
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Mesangiumzellen und Hepatocyten könnten durch zellspezifische   
Regulationsmechanismen erklärt werden. Weiterhin wurde in beiden Zellsystemen 
die mRNA-Expression der mHMG-CoA Synthase unter allen eingesetzten 
hypoxischen Bedingungen reduziert. Dies bedeutet, dass die Ketogenese O2-
abhängig abläuft und unter Hypoxie herunter reguliert  wird. 
4.) Der letzte Teil der vorliegenden Arbeit befasst sich mit der Regulation der CPT-
Iα Expression durch exogene sPLA2s in Mesangiumzellen und Hepatozyten. Auf 
Grund früherer Arbeiten war bekant, dass bei entzündlichen Prozessen sPLA2s in 
großen Mengen in Extrazellularräume und Körperflüssigkeiten sezerniert werden, 
um dort ein breites Spektrum von Fettsäuren aus Phospholipiden freizusetzen. Die 
Arbeitshypothese war, dass die auf diesem Weg freigesetzten Fettsäuren eine 
Hochregulation der CPT-Iα induzieren könnten. Es konnte gezeigt werden, dass es 
in Mesangiumzellen, die mit rekombinanten oder gereinigten sPLA2s exogen 
behandelt wurden, zu einer Erhöhung der CPT-Iα Expression auf Protein-, mRNA- 
und Promotor-Ebene kommt. In Hepatocyten konnte ebenfalls eine verstärkte CPT-
Iα−Proteinexpression festgestellt werden. Ein synergistischer Effekt mit TNF-α 
konnte nur auf Protein- und mRNA-Ebene, nicht jedoch auf Promotorebene 
beobachtet werden, was auf einen gemeinsamen Mechanismus der Promotor-
Aktivierung durch sPLA2s und TNF-α schließen lässt. Wurden die Zellen 
gleichzeitig mit den  Mitogen-aktivierten-Protein-Kinase (MAPK)-Inhibitoren PD 
98059 and  U0126 behandelt, wurde diese Hochregulation der CPT-Iα gehemmt. 
Daraus kann gefolgert werden, dass der sPLA2-induzierte Effekt auf die CPT-Iα -
Expression durch die bereits bekannte sPLA2-induzierte Aktivierung der MAPK 
vermittelt wird. In Mesangiumzellen wurde weiterhin gezeigt, dass sPLA2s in 
Koinkubation mit TNF-α die mRNA Expression der mHMG-CoA Synthase stark 
induziert .  
In dieser Arbeit konnte also gezeigt werden, dass unter den gewählten 
proinflammatorischen Bedingungen die CPT-Iα sowohl auf der Ebene der 
Genexpression als auch auf Proteinebene reguliert wird. Auch die an die CPT-Iα 
gekoppelte mHMG-CoA Synthase wird in ihrer mRNA-Expression moduliert, 
sodass Effekte auf die Ketogenese zu vermuten sind. Zukünftige Arbeiten könnten 
zeigen, ob CPT-Iα als ein mögliches Target für die Entwicklung neuer Therapie-
Strategien zur Verbesserung der Energiebilanz und damit auch der 
Überlebungsrate bei entzündlichen Erkrankungen dienen kann.     VII.  Appendix 
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